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Abstract 
Characterization of Mannheimia haemolytica-specific bacteriophages 
 
 Mannheimia haemolytica is the principal bacterial agent associated with bovine 
respiratory disease (BRD). It has a significant economic impact on the beef feedlot 
industry. The current methods for BRD prevention and treatment have various problems 
and limitations, especially with reports of increased antimicrobial resistance in M. 
haemolytica. Bacteriophage therapy presents a novel method to mitigate M. haemolytica. 
This study aimed to isolate strictly lytic M. haemolytica-specific bacteriophages from 
bovine nasopharyngeal swabs and feedlot trough water. This was accompanied by an 
extensive characterization of temperate bacteriophages induced from representative 
strains of a M. haemolytica collection. Phage morphology, host specificity, genomic 
diversity, and comparative genomics were determined. Even though temperate 
bacteriophages are not ideal candidates for phage therapy, they can be engineered or 
modified to serve this function. Genome sequences of selected temperate bacteriophages 
also provide a foundation for future studies on the biology of these microorganisms. 
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CHAPTER ONE 
1.1 Introduction 
 The occurrence of bovine respiratory disease (BRD) continues to be one of the 
major health issues in the global cattle production industry. The morbidity and mortality 
associated with BRD have significant economic consequences on the feedlot industry 
(Duff and Galyean, 2007; Edwards, 1996). An overview of BRD is provided including 
various factors that contribute to its disease process and outcome, together with 
symptoms, pathology, and methods currently available to control and prevent BRD. 
Mannheimia haemolytica has been identified as the principal bacterial pathogen 
associated with BRD. It encodes several important virulence factors responsible for BRD 
pathogenesis and has shown increasing resistance to many antimicrobial agents 
(Desmolaize et al., 2011). Based on previous studies, bacteriophage therapy presents an 
innovative area of research for preventing bacterial infections. By understanding basic 
phage biology and phage characteristics during the infection and reproduction process, 
one can explore the possibility of using bacteriophage as a means of controlling BRD in 
cattle.  
 
1.2 Economics 
 According to a cross-sectional survey conducted in the United States, BRD is the 
leading cause of morbidity and mortality in feedlots (Woolums et al., 2005), with 
approximately 75% of cattle morbidities and up to 70% of mortalities being linked to this 
disease (Edwards, 1996). Mortality from BRD and the expense of medicine and labour to 
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treat BRD contribute significantly to production costs. Feedlot performance and carcass 
traits are also negatively affected by BRD (Duff and Galyean, 2007; Gardner et al., 1999). 
Montgomery et al. (1984) and Roeber et al. (2001) reported that BRD negatively affected 
marbling scores, quality and yield grade. Calves receiving three or more medical 
treatments for BRD returned considerably less profit than calves that were not treated 
(Fulton et al., 2002). It is estimated that BRD results in losses of over $690 million 
annually in the United States (Badcock, 2008). When combined with expenses associated 
with BRD, this figure is estimated at as much as one billion dollars (Hodgins and 
Shewen, 2004a).  
 
1.3 Bovine respiratory disease (BRD) 
1.3.1 BRD/BRDC 
 Nowadays, the term bovine respiratory disease (BRD) is often being used 
interchangeably with bovine respiratory disease complex (BRDC) and shipping fever. 
Originally, BRDC was defined as three major clinical entities: 1) enzootic pneumonia of 
calves, 2) shipping fever complex, and 3) atypical interstitial pneumonia (Lillie, 1974). 
To avoid confusion in this paper, BRD refers to the clinical disease condition itself, while 
BRDC refers to various bacterial, viral, and environmental causes associated with this 
disease. The occurrences of BRD in newly-weaned or received cattle continue to be the 
major health problem for the US beef cattle industry (Duff and Galyean, 2007). While 
BRD is ultimately an infectious respiratory viral/bacterial disease in cattle, there are 
many potential exacerbating factors and outcomes that complicate the problem. Moreover, 
 2
the etiology of BRD is complex and multi-factored and can be categorized into three 
main components, bacterial, viral, and environmental/physiologic stressors.  
 
1.4 Factors that contribute to BRD 
1.4.1 Bacterial agents 
 The main bacterial pathogens of BRD include M. haemolytica, Pasteurella 
multocida, Histophilus somni (formerly Haemophilus somnus) and Mycoplasma bovis 
(Apley, 2006; Griffin et al., 2010; Pandher et al., 1998). These bacteria are ubiquitous in 
the cattle population as normal nasopharyngeal commensals (Panciera and Confer, 2010). 
When cattle encounter stress and viral or parasitic infections that impair health and 
suppress the host immune system, a window of opportunity is provided for secondary 
bacterial pathogens to colonize and reproduce in the upper respiratory tract (Griffin et al., 
2010; Irsik, 2007). Regardless of the initiating events, M. haemolytica is considered to be 
the predominant bacterial pathogen associated with BRD (Duff and Galyean, 2007; Gioia 
et al., 2006; Griffin et al., 2010). It is the most common bacterium recovered from BRD 
cattle and therefore has received the most attention by researchers, even though mixed 
bacterial and viral infections are often associated with BRD. Pneumonia caused by these 
bacterial pathogens is the most significant cause of BRD associated morbidity and 
mortality. These pathogens may form similar pneumonic lesions even though they carry 
distinctive and common virulence factors (Griffin et al., 2010). 
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1.4.2 Environmental/Physiological agents 
 The current marketing and transport system used for feeder cattle in North 
America naturally impose stresses on animals (Duff and Galyean, 2007; Griffin et al., 
2010). Various stressors are often introduced when calves are weaned and transported to 
a sale barn. Environmental stressors during transportation may include chilling and 
overheating, dehydration, starvation, and exhaustion depending on weather conditions 
(Rice et al., 2007). Depending on feedlot management practices, newly received calves 
may experience various degrees of stress caused by commingling, processing, and 
introduction to new feed and environments (Bowland and Shewen, 2000; Duff and 
Galyean, 2007). For instance, commingling of calves from various sources may destroy 
the social hierarchy and impose additional stress on the animals (Loerch and Fluharty, 
2000). These stressors impose either psychological or physical pressure on the animals 
and often increase host susceptibility to BRD due to compromised immune responses 
(Duff and Galyean, 2007; Srikumaran et al., 2007). This is evident especially when 
animals are exposed to high levels of infectious agents in these situations (Jericho. 1979), 
and when stressors cause transient elevation of plasma cortisol levels along with a 
decrease in serum complement activity in calves (Rice et al., 2007; Srikumaran et al., 
2007). In these environments, viral infection or inhaled irritants can lead to cellular 
damage in the upper respiratory tract (Irsik, 2007), and provide a window of opportunity 
for secondary pathogens such as M. haemolytica to colonize and become established. To 
further complicate the problem, animals are often grouped together with other cattle with 
unknown disease and vaccination status (Griffins et al., 2010).  
 
 4
1.4.3 Viral agents 
 Multiple viruses have been shown to be associated with BRD (Bowland and 
Shewen, 2000; Duff and Galyean, 2007; Fulton, 2009; Griffins et al., 2010). Co-infection 
with a virus and a bacterium does occur and may result in weakened clearance of 
infecting bacteria and lesions within the respiratory tract (Griffins et al., 2010). The major 
viral agents linked to BRD are bovine viral diarrhea virus (BVDV), bovine respiratory 
syncytial virus (BRSV), bovine herpes virus-1 (BHV-1), infectious bovine rhinotracheitis 
virus (IBR), and parainfluenza type 3 (PI-3) virus (Apley, 2006; Edwards, 2010; Griffins 
et al., 2010; Hodgson, 2005). Infection with BVDV leads to damage of alveolar 
macrophages thus inducing immunosuppression of animals (Babiuk et al., 2004). 
Infection with BRSV results in loss of cilia or necrosis of bronchial and bronchiolar 
epithelial cells, and reduces phagocytosis and opsonization by alveolar macrophages 
(Griffins et al. 2010). Infections of BHV-1 can spread to lower respiratory tract and cause 
necrosis of epithelial cells (van Vuuren, 2004). Infections with PI-3 are associated with 
little or no clinical symptoms in cattle, but do cause necrosis of the ciliated epithelium 
(Griffins et al., 2010). Most of these viruses target respiratory epithelial and ciliated cells 
of the animal. Viral infection in many cases promotes necrosis of epithelial cells and 
reduces their capacity for mucociliary clearance of agents from the respiratory tract. The 
accumulation of fluid and cellular debris plus formation of surface lesions in the 
respiratory system provide an ideal environment for secondary bacterial infection 
(Griffins et al., 2010).  
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1.5 Symptoms and Pathology of BRD 
1.5.1 Host innate immunity 
 The respiratory epithelial surface of healthy cattle provides mechanical, chemical 
and microbiological barriers to prevent pathogen infection (Frank, 1984). Many bacteria 
including potential pathogens such as M. haemolytica and other members of the 
Pasteurellaceae may exist as commensals in the upper respiratory tract and nasopharynx 
of healthy animals (Cusack et al., 2003; Griffins et al., 2010). Mucus secretion prevents 
the adherence of bacteria, and the epithelial cilia provide constant upward movement of 
the mucus that carries potential pathogens. There are also bactericidal proteins and 
peptides on the epithelial surfaces of the lung. These bind to the cell surface of 
pathogens, promoting phagocytosis by resident macrophages and neutrophils (Griffins et 
al., 2010).  
 The lung expresses many extracellular, cell surface, endosomal, and cytoplasmic 
receptors that recognize conserved substances (teichoic acid, lipopolysaccharide, 
cytokine-phosphate-guanine DNA, etc.) produced by microbial pathogens (Ackermann et 
al., 2010). For instance, there are cell surface Toll-like receptors on the lung epithelia. 
Activation of these receptors can lead to nuclear factor kappa B activity and 
inflammatory reactions, or induction of interferon genes (Ackermann et al., 2010). 
Cytosol receptors such as nucleotide oligomerization domain-like receptors can recognize 
pathogens in the cytoplasm and trigger cell activation that leads to proinflammatory 
responses (Ackermann et al., 2010). These elements together provide the host with 
defence mechanisms against pathogens. To a healthy animal, some of the bacterial and 
viral agents associated with BRD may present little or no harm to the host. However, 
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under stress, the innate immune system is compromised and increased bacterial 
colonization may occur in stressed animals (Highlander, 2001). As BRD is typically 
manifested through a primary viral infection of the upper respiratory tract, this 
predisposes cattle to secondary bacterial infections (Edwards, 2010; Hodgson, 2005). As 
the disease progresses, commensal organisms may migrate into the lower respiratory tract 
and eventually the lungs, where bacterial infections can cause significant tissue damage. 
It is the combinations of stress, viral and bacterial agents that cause the clinical symptoms 
of BRD and even death. 
 
1.5.2 Symptoms 
 As early as 7 to 10 days after calves arrive at the feedlot, clinical signs of BRD 
can be detected (Rice et al., 2007). Newly received or stressed animals are considered to 
be at high risk of developing BRD. Morbid cattle are usually identified visually, when 
animals display various signs of discomfort. Changes in the behaviour and appearance of 
individuals such as nasal/ocular discharge, depression, lethargy, anorexia, fever, 
increased respiratory rate, and moist cough, or combinations of above may all be 
indicative of BRD (Duff and Galyean, 2007; Griffins et al., 2010; Sowell et al., 1999). 
More severe symptoms may include respiratory distress, encrusted muzzles, excessive 
tear production, and dyspnea (Griffins et al., 2010). A common observation in diseased 
calves is a stressed stance with elbows abducted and neck extended (Duff and Galyean, 
2007; Hodgins and Shewen, 2004a; Rice et al., 2007; Zecchinon at al., 2005).  
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1.5.3 Pathology 
 Regardless of the initiating event, progression of the disease often results in 
secondary bacterial infection of the lower respiratory tract. Eventually this may lead to 
severe bacterial pneumonia (Panciera and Confer, 2010), a condition that is frequently 
fatal. Often, calves develop pneumonia shortly after arrival at the feedlot (Gagea et al., 
2006; Rice et al., 2007). The major cause of death in animals suffering from BRD is 
acute pleuropneumonia (Griffins et al., 2010; Rice et al., 2007), also called serofibrinous 
pleuropneumonia (Hodgins and Shewen, 2004a; Fulton et al., 2002), or multifactorial 
fibrinonecrotizing pneumonia (Highlander et al., 2000). In general, necropsy shows 
bilateral, cranioventrally distributed, very firm, minimally compressible lung 
consolidation (Griffins et al., 2010; Panciera and Confer, 2010). Consolidated lobes 
usually have a marbled appearance and infected areas accumulate yellow fibrin and 
edema (Griffins et al., 2010; Panciera and Confer, 2010). Chronic BRD infections are 
characterized by coagulation necrosis outlined with pale fibrous tissue and extensive 
adhesions formed by fibrin deposits in the pleural and pericardial cavities (Fulton et al., 
2002; Griffins et al., 2010; Hodgins and Shewen, 2004a). 
 
1.6 Management/Prevention of the BRD 
1.6.1 Management 
 For the past three decades, efforts have been made to reduce BRD incidence 
through improved management strategies and early recognition of sick animals (Griffins 
et al., 2010). Reducing potential stressors and better management practices of highly 
susceptible animals seems to decrease the incidence and severity of BRD infection 
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(Cusack et al., 2003; Griffins et al., 2010). According to Gorden and Plummer (2010), 
prevention practices of BRD in dairy calves include the development and maintenance of 
a robust immune system, sound nutrition, proper vaccination, biosecurity, and provision 
of adequate ventilation. Even though these practices can be implemented to improve 
cattle health, they may seem impractical in the view of feedlot cattle producers and 
difficult to achieve in a cattle production system. An effective means of minimizing 
weaning stress and decreasing BRD morbidity is by pre-conditioning or pre-weaning of 
the cattle (Cusack et al., 2003; Duff and Galyean, 2007). These programs may include a 
weaning period, vaccinations, antihelminthic treatment, castration, dehorning, and 
acclimatization to new feed and environment (Thomson and White, 2006). However, 
these programs are not widely implemented as they require additional effort on behalf of 
the cow-calf producer that is not economically recovered (Duff and Galyean, 2007; 
Waggoner et al., 2005). Identifying the causative agents of BRD aids proper treatment. A 
nasal swab culture can be obtained easily for identifying the species responsible for 
causing bacterial pneumonia (De-Rosa et al., 2000). Antibiotic susceptibility of the 
isolated bacteria can be determined from the nasal swab as well (De-Rosa et al., 2000). 
However, laboratory tests for the above detections typically require additional time and 
cost (Duff and Galyean, 2007), which make them less useful in a therapeutic treatment 
program. Due to the complexity of BRD, even with a significant increase in the amount 
and quality of research, vaccination and therapeutic practices lack efficacy (Griffin et al., 
2010). 
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1.6.2 Metaphylaxis/Prophylaxis 
 The use of metaphylactic antimicrobial therapy can be considered as prevention 
and treatment as cattle arriving at feedlot facility not only may be at risk of developing 
BRD, but also actively experiencing various stages of the disease process (Duff and 
Galyean, 2007; Lofgreen, 1983; Young, 1995). Prophylactic medication programs are 
also effective against BRD bacterial pathogens such as M. haemolytica (Frank and Duff, 
2000; Frank et al., 2002). The metaphylactic method is based on the concept of treating 
the entire population at a single point in time to eliminate or minimize an expected 
outbreak of disease. Treatment of the population is often preferable due to the diagnostic 
challenges of identifying individual BRD cases in calves (Nickell and White, 2010) and 
metaphylaxis has proven to be more efficient and cost effective in controlling bacterial 
pathogens associated with BRD (Edwards, 2010). The use of metaphylaxis during 
relocation of cattle has been successfully used to reduce the incidence of BRD 
(Donkersgoed et al., 1993). Moreover, administrating long-acting antibiotics to newly 
arrived cattle has been shown to significantly reduce morbidity and improve rate of gain 
(Duff and Galyean, 2007; Rice et al., 2007; Thomson and White, 2006). Typical 
antimicrobial compounds administered to cattle include the injectables: ceftiofur, 
oxytetracycline, enrofloxacin, florfenicol, danofloxacin, tilmicosin, tulathromycin, tylosin, 
chlortetracycline, spectinomycin, erythromycin and penicillin (Carson et al., 2008; Fulon, 
2009; Nickell and White, 2010; Thomson and White, 2006). In addition, there are several 
water and in-feed medications such as sulfa drugs, tetracyclines and tylosin (Fulton, 
2009). These antimicrobials are listed in Table 1.1. A newer non-steroidal anti-
inflammatory agent, flunixin meglumine was made available in 2009. 
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Table 1.1. Typical antimicrobial compounds administered to cattle to control or prevent 
bovine respiratory disease. 
Antimicrobial Family Trade names Route of Administration 
ceftiofur cephalosporin Excede / Naxcel Injectable 
oxytetracycline tetracycline  Terramycin / Oxy-Tet, etc Injectable 
enrofloxicin fluoroquinolone Baytril  Injectable 
florfenicol thiamphenicol Nuflor Injectable 
danofloxacin fluoroquinolone A180 Injectable 
tilmicosin macrolide  Pulmotil / Micotil Injectable 
tulathromycin macrolide  Draxxin Injectable 
tylosin macrolide Tylan Injectable / Feed 
chlortetracycline tetracycline  Aureomycin  Injectable / Feed 
spectinomycin aminocyclitol Trobicin / Spectam Injectable 
erythromycin  macrolide  Erythro / Gallimycin Injectable 
penicillin  beta-lactam Crystacillin / Flo-Cillin, etc Injectable 
sulfas sulfonamides Tribrissen / Trivetrin Feed 
tetracyclines  tetracycline  Panmycin / Polyotic Feed 
 
 
1.6.3 Vaccination 
 The combination of vaccination and management strategies can provide calves an 
opportunity to build immunity during a time when stress and disease challenge is 
minimal (Edwards, 2010). However, due to the current feedlot marketing system, 
vaccination and background history of newly received cattle may be vague or unknown. 
Therefore, it becomes crucial for the feedlot producer to obtain vaccination records from 
the source of origin of the calves to help determine immune status (Edwards, 2010). 
There are concerns when administering vaccines to cattle. Immunity usually takes 2 to 3 
weeks to develop, so timing is critical. Moreover, in order to elicit protective immunity, 
multiple doses of vaccine may be required. This adds work and expense for the cow-calf 
producer. While administering a vaccine provides the immune system exposure to the 
antigen, this does not guarantee a positive immune response from the animal (Edwards, 
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2010). Even though vaccination against BRD is a common practice in feedlot 
management, studies supporting its efficacy are limited (Bowland and Shewen, 2000; 
Lorenz et al., 2011; Perino and Hunsaker, 1997). Common commercial vaccination 
products available for BRD prevention include viral antigens for BHV-1 (IBR), BVDV, 
PI3, and BRSV (Table 1.2) (Bowland and Shewen, 2000; Duff and Galyean, 2007; 
Edwards, 2010), with some of these vaccines being integrated into preconditioning 
programs (Duff and Galyean, 2007). Common bacterial antigens used for control of BRD 
include M. haemolytica and H. somni. These antigens can be used singly or in a 
combined viral and bacterial vaccine, and most products can be administered 
subcutaneously (Edwards, 2010). Vaccination against M. haemolytica has produced 
mixed results. These vaccines are problematic as they require serological information of 
the infecting strain to be effective and cross-protection against other serotypes is 
generally not possible (Kehrenberg et al., 2001). However, other studies have shown 
reduced morbidity, mortality, and relapses with the use of M. haemolytica bacterin-toxoid 
vaccines (Fulton, 2009; MacGregor et al., 2003). 
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Table 1.2. Typical commercial vaccination products for controlling bovine respiratory-
associated viruses and bacteria. 
 
 Target agents 
Manufacture & trade names BHV-1 (IBR) BVDV  PI3 BRSV
M. 
haemolytica
H. 
somni 
AgriLabs / Titanium® 5 a √ √ √ √   
AgriPharm / CovertTM10 b √ √ √ √   
Aspen / TiterVac® 10 a √ √ √ √   
Bayer / BRSV Vac® 4 a √ √ √ √   
Boehringer Ingelheim 
Vetmedica / SentryTM 4 d √ √ √ √   
Durvet / DurvacTM 5 a √ √ √ √   
Novartis / Vira Shield® 5 e √ √ √ √   
Pharmacia & Upjohn / Herd-
VacTM 3 c √ √ √    
Pfizer / Bovi-Shield® Gold 5 a √ √ √ √   
Ayerst / Response® d     √  
Biowest / Somnu-Star PhTM d     √ √ 
Pfizer / One Shot TM c     √  
Pfizer / SomubacTM d      √ 
Pfizer / Resvac® 3 
BRSV/SomubacTM d √ √ √ √  √ 
Vetrepharm / VirabosTM-4 + 
H. somnus d √ √ √ √  √ 
 
Recommended dosage: 
a 1 dose primary vaccination followed by 1 dose of BRSV vaccine 2-4 weeks later. 
Annual revaccination is recommended. 
b 1 dose primary vaccination, repeat after 2-4 weeks and once annually. 
c 1 dose primary vaccination. 
d 2 doses primary vaccination (2-4 weeks apart). Annual revaccination is 
recommended. 
e 1 dose primary vaccination and revaccinate in 4-5 weeks. 
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1.7 Mannheimia haemolytica 
1.7.1 The organism 
M. haemolytica is a weakly haemolytic, Gram-negative non-spore-forming 
coccobacillus (Griffin et al., 2010; Rice et al., 2007; Zecchinon et al., 2005). It often 
shows up as a complicating agent in BRD and various researchers suggest M. 
haemolytica is the principal causative agent of the disease (Duff and Galyean, 2007; 
Gioia et al., 2006; Griffin et al., 2010; Zecchinon et al., 2005). Among the bacterial 
agents associated with BRD, M. haemolytica is the most highly characterized as it is the 
bacterium most frequently recovered from cattle suffering from BRD. Beginning in the 
late 1970s and the early 1980s, a major BRD research emphasis was placed on M. 
haemolytica as the primary etiological agent, and challenge studies were performed 
(Fulton, 2009). M. haemolytica is characterized as being an oxidase-positive, indole-
negative, fermentative, non-motile facultative anaerobe (Griffin et al., 2010; Rice et al., 
2007). M. haemolytica, formally known as Pasteurella haemolytica, now belongs to the 
class Gamma-proteobacteria, order Pasteurellales, and family Pasteurellaceae (Griffin et 
al, 2010; Zecchinon et al., 2005). There are presently six species within the Mannheimia 
genus: M. haemolytica, Mannheimia granulomatis, Mannheimia glucosida, Mannheimia 
ruminalis, Mannheimia varigena, and Mannheimia caviae (Christensen et al., 2011; 
Gioia et al., 2006). There are 12 capsular serotypes in M. haemolytica: A1, A2, A5, A6, 
A7, A8, A9, A12, A13, A14, A16, and A17 (Fulton, 2009; Katsuda et al., 2007; 
Srikumaran et al., 2007). The predominant serotype isolated from healthy cattle is 
serotype A2, but both serotype A1 and A2 have been found to colonize the bovine upper 
respiratory tract (Hodgins and Shewen, 2004b), with serotype A2 generally considered as 
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being non-pathogenic to cattle. However, serotype A2 does cause pneumonia in sheep 
(Highlander, 2001; Rice et al., 2007). When an animal’s immune system becomes 
compromised, the commensal relationship is disrupted. M. haemolytica becomes 
pathogenic as it migrates and infects the lower respiratory tract. At this stage, A1 
becomes the predominant serotype and causes characteristic bronchopneumonia (Griffin 
et al., 2010; Hodgins and Shewen, 2004b), and is the most frequent serotype isolated 
from pneumonic tissue (Gioia et al., 2006; Griffin et al., 2010; Katsuda et al., 2007; 
Pandher et al., 1998). There has been an increased prevalence of serotype A6 associated 
with BRD in the United Kingdom and the United States (Hodgins and Shewen, 2004b; 
Kehrenberg et al., 2001; Purdy et al., 1997). As a result, serotype A1 and A6 are now 
considered to be the virulent strains of M. haemolytica associated with BRD. Studies also 
show serotype A1 and A6 have extremely similar mechanisms of pathogenicity, aside 
from capsule differences (Davies et al., 2002; Srikumaran et al., 2007). 
 
1.7.2 Virulence factors 
 Numerous papers have been published that describe the virulence and 
pathogenesis of M. haemolytica. Virulence factors allow M. haemolytica to evade 
clearance and avoid host defences while rapidly reproducing in the lower respiratory tract 
(Griffin et al., 2010). M. haemolytica has a number of virulence factors that are 
responsible for adherence and colonization within the respiratory tract. Virulence factors 
include adhesion proteins, capsular polysaccharides, lipopolysaccharide, fimbriae, 
sialoglycoprotease, and neuraminidase (Rice et al., 2007). Capsular polysaccharides are 
used for adherence and invasion, and impair the phagocytic ability of neutrophils (Apley, 
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2006; Rice et al., 2007). Sialoglycoprotease is believed to reduce the effectiveness of 
opsonizing antibodies (Lee and Shewen, 1996). Outer membrane proteins provide 
protective immune responses and allow M. haemolytica to replicate in a low-iron host-
regulated environment (Apley, 2006; Highlander, 2001; Rice et al., 2007). Adhesins play 
a crucial role in the colonization process (Hodgins and Shewen, 2004b; Zecchinon et al., 
2005). Neuraminidase also promotes colonization by reducing respiratory mucosal 
viscosity, thus allowing bacteria access to the cell surface (Zecchinon et al., 2005). One 
critical virulence factor is the lipopolysaccharide (LPS) cell wall component. It is 
responsible for the macrophage activation associated with endotoxin and causes 
haemorrhage, edema, hypoxemia, and acute inflammation in the host (Breider et al., 1990; 
Griffin et al., 2010). Among these virulence factors, leukotoxin (LKT), a pore-forming 
calcium-dependent cytotoxin belonging to the RTX family (Czuprynski et al., 2004; 
Gioia et al., 2006; Highlander et al., 2000), is considered as the main virulence factor in 
M. haemolytica pathogenesis (Gioia et al., 2006; Zecchinon et al., 2005). It is closely 
associated with pneumonic damage and it is responsible for lysis of ruminant leukocytes 
and platelets (Fulton, 2009; Gioia et al., 2006; Rice et al., 2007). Leukotoxin also allows 
the bacterium to evade destruction by the host's phagocytic cells (Rice et al., 2007), with 
its influence being concentration dependent. At low concentrations, LKT induces 
apoptosis by activating leukocytes to release various inflammatory substances including 
reactive oxygen intermediates, eicosanoids, and cytokines (Czuprynski et al., 2004; 
Hodgins and Shewen, 2004b). Higher LKT concentration impairs leukocyte function, 
resulting in cellular death and the formation of lung lesions and vascular damage 
(Czuprynski et al., 2004; Hodgins and Shewen, 2004b; Rice et al., 2007).  
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1.7.3 Antimicrobial resistance 
The common use of antibiotics for disease prevention and growth promotion in 
domestic animals can potentially lead to the selection of antimicrobial-resistant (AMR) 
bacteria. Therefore, all bacterial pathogens associated with BRD could potentially 
develop resistance to antimicrobials. This discussion only describes AMR as it relates to 
M. haemolytica since it is the primary bacterial causative agent of BRD in cattle. 
Treatment and prevention of BRD associated with M. haemolytica usually entails 
prophylactic or metaphylactic medication with antimicrobials. Incorrect or ineffective 
usage of antimicrobial treatment may result in an increased occurrence of AMR in M. 
haemolytica (Hodgins and Shewen, 2004b; Watts et al., 1994). In order for treatment to 
be effective, antimicrobials must be administered very early in the disease process (Irsik, 
2007). M. haemolytica has shown increasing resistance to many antimicrobial agents 
(Desmolaize et al., 2011). For instance, M. haemolytica is commonly found to be 
resistant to aminoglycosides, β-lactams, sulfonamides, streptomycin, macrolides, 
sulfamethazines, and tetracyclines (Highlander, 2001; Hodgins and Shewen, 2004b; 
Watts et al., 1994), and resistance to fluoroquinolones has been recently observed 
(Hodgins and Shewen, 2004b). In addition, due to delayed laboratory analysis, a high 
degree of variability is observed among isolates originating from the same animal source, 
and resistance rates vary over time (Hodgins and Shewen, 2004b). Most of these 
resistance genes seem to be associated with small or large plasmids, as well as 
transposons (Kehrenberg and Schwarz, 2001; Watts et al., 1994; Zecchinon et al., 2005). 
M. haemolytica is considered to be naturally competent (Gioia et al., 2006), and the 
resistance genes may be acquired by horizontal gene transfer (Kehrenbreg et al., 2001). 
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The increased incidence of AMR is a major concern in feedlot industry and monitoring of 
antimicrobial susceptibility in M. haemolytica provides insight into effective 
antimicrobial therapies for bovine pneumonia (Katsuda et al., 2009). Similarly, a greater 
emphasis must be placed on therapies that reduce or minimize the selection of resistant 
mutants (Griffin et al, 2010).  
 
1.8 Introduction to Bacteriophage 
1.8.1 Bacteriophage 
Viruses are a complex and diverse group of microorganisms. Viruses that infect 
bacteria are called bacteriophages (Willey et al., 2008), or “phages” for short 
(Ackermann, 2003). Bacteriophages were first discovered independently by Frederick 
Twort and Felix d’Herelle in the early 1900s (Ackermann, 2003; Adams, 1959; 
Duckworth, 1976; Kutter and Sulakvelidze, 2005; Willey et al., 2008). They are probably 
the most abundant biomass on earth, both in terrestrial and aquatic ecosystems (Kutter 
and Sulakvelidze, 2005; Willey et al., 2008). The global population of tailed phages alone 
is estimated to be in the order of 1031 entities (Hendrix et al., 1999), and there can be up 
to 108 viral particles per millilitre in various aquatic systems (Wommack and Colwell, 
2000). Bacteriophages have a major influence on the structure, activity, temporal 
dynamics, biological diversity and evolution of microbial communities (Letarov and 
Kulikov, 2009). Bacteriophages contribute considerably to bacterial genetic variability. 
They may serve as agents of lateral gene transfer (Canchaya et al., 2003a), and carry 
virulence factors that confer pathogenicity to their host (Willey et al., 2008). Early 
research on bacteriophage was concentrated on characterizing physical, genetic, 
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biochemical, physiological, and morphological features, with a few model phages such as 
phage lambda (λ) and T-series phage that were studied extensively (Clark and March, 
2006; Kutter and Sulakvelidze, 2005). Bacteriophage DNA, mRNA, and gene regulation 
were identified and characterized by exploring these model phage systems (Clark and 
March, 2006).  
Shortly after the discovery of bacteriophages, they have been widely used to treat 
bacterial infections. Despite the discovery of antimicrobials and decreased interest in the 
West, phage therapy continued to be applied extensively in the former Soviet Union 
(Clark and March, 2006; Kutateladze and Adamia, 2010). A vast amount of therapeutic 
phage work has been conducted by the Georgia Eliava Institute of Bacteriophage, 
Microbiology and Virology in Georgia (Clark and March, 2006; Kutateladze and Adamia, 
2010). In the former Soviet Union, phage preparations have been used for therapy, 
prophylaxis, and diagnosis of numerous bacterial infections (Kutateladze and Adamia, 
2010). It was not until the 1980s that phage research started to shift towards development 
of new techniques that utilize phages and their enzymes (Kutter and Sulakvelidze, 2005). 
This included the use of phage enzymes and vectors in genetic engineering, phage display 
and detection technologies (Kutter and Sulakvelidze, 2005). Nevertheless, they were 
utilized mainly as research tools at this time in the west. Research on phage biology, 
including phage function, distribution within natural microbial communities, and their 
potential therapeutic application, was largely ignored until recently (Clark and March, 
2006; Kutter and Sulakvelidze, 2005). 
 Phage ecology has developed rapidly with advances in molecular biology, 
including genomic and metagenomic studies, and methodologies applied in detection and 
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analysis. Recently, there has been an increased interest in potential phage applications in 
industry and medicine. For instance, bacteriophages have been proposed as new 
candidates for vaccines, a means of detecting pathogenic bacteria, a therapy against 
antimicrobial resistant bacteria, and a tool for various proteins, peptides, or antibodies 
screening applications (Clark and March, 2006). 
 
1.8.2 Classification System 
 Soon after the discovery of bacteriophages, many researchers proposed various 
schemes of classification (Kutter and Sulakvelidze, 2005). However, most of these 
schemes were not accepted by the scientific community, and researchers continued to 
come up with revised schemes for viral classification. A classification scheme proposed 
in 1962 by Lwoff, Horne, and Tournier was adopted later by the Provisional Committee 
on Nomenclature of Viruses (PCNV). This scheme was known as the Lwoff, Horne, and 
Tournier (LHT) system. Classification was based on the virus’ nucleic acid, capsid shape, 
presence of an envelope, and number of capsomers. A few years later, the PCNV became 
the International Committee on Taxonomy of Viruses (ICTV), which is the current 
organization responsible for standardizing the classification of all viruses, including 
bacteriophages (Kutter and Sulakvelidze, 2005; Willey et al., 2008). The committee 
preserved most of the taxa organized by the LHT scheme, even though it no longer uses 
the same classification system. The ICTV classification system now considers the nature 
of nuclear acids, particle structure, nucleotide or amino acid sequences, and other 
available information such as natural host range, pathogenicity, and mode of transmission 
in its classification system (Büchen-Osmond, 2003; Kutter and Sulakvelidze, 2005; 
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Willey et al., 2008). The current (2009) ICTV virus taxonomy contains 6 orders, 87 
families, 348 genera, and 2,285 species. Due to the difficulty of establishing evolutionary 
relationships, there are still many viral families that are not assigned to an order, and 
ICTV has yet to develop complete taxonomical structures above the family level (Van 
Regenmortel et al., 2000; Willey et al., 2008). In addition, there are genera that cannot be 
grouped with other taxa due to lack of data (Kutter and Sulakvelidze, 2005). An 
alternative classification scheme used by many virologists is the Baltimore system. This 
system complements the ICTV classification as it focuses on the genome of the virus and 
the process of viral mRNA synthesis (Willey et al., 2008). The majority of viruses in the 
taxonomical system now are viruses of eukaryotes and bacteria, with few archaeal viruses 
been present (Willey et al., 2008).  
 
1.8.3 Current Classification 
 Bacteriophages are sometimes defined as viruses of prokaryotes and they have 
been shown to infect more than 140 bacterial genera (Ackermann, 2001; Ackermann, 
2003; Kutter and Sulakvelidze, 2005). They are extremely diverse in terms of their 
structural, physiological, and biological properties (Casjens, 2003; Kutter and 
Sulakvelidze, 2005). Currently, the bacteriophages are classified into one order, 13 
families, and 34 genera (Lavigne et al., 2008 and 2009). The taxonomy of phages is still 
under development, as more phages are being discovered and characterized. Almost all 
bacteriophages contain double-stranded DNA, but phages with single-stranded DNA, 
single-stranded RNA, or double-stranded RNA also exist. Some phages may also possess 
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lipid envelopes or internal vesicles. There are four types of virions in bacteriophage: 
tailed, polyhedral, filamentous, and pleomorphic (Ackermann, 2003). 
This review will focus on tailed phages alone as they represent the largest and 
most prevalent group among bacteriophages, whereas tailless (polyhedral, filamentous, 
and pleomorphic) phages constitute less than 4% of all phages currently recognized 
(Ackermann, 2001). Tailed phages have been classified to a single order, Caudovirales 
(Ackermann, 1998; Ackermann, 2003; Maniloff and Ackermann, 1998). Capsid structure 
is an important morphological trait utilized for bacteriophage classification. Typical 
tailed phage particles have icosahedral heads (capsids) and helical tails. This combination 
of cubic symmetry and helical tail is called binary or binal symmetry (Kutter and 
Sulakvelidze, 2005; Lwoff et al., 1962; Willey et al., 2008). They consist of a non-
enveloped protein coat (capsid) and linear double-stranded DNA (Ackermann, 2003; 
Kutter and Sulakvelidze, 2005). Tailed phage DNA composition often reflects that of the 
host bacterium, but in rare cases can contain unusual bases such as 5-
hydroxymethylcytocine (Ackermann, 2003; Kutter and Sulakvelidze, 2005). The capsids 
are constructed from groups of capsomers (usually 5-6 protein subunits) that can be 
difficult to observe (Ackermann, 2003; Kutter and Sulakvelidze, 2005) and tails are either 
true helices or stacked disks that often carry structures such as base plates, spikes, or 
fibers (Ackermann, 2003; Kutter and Sulakvelidze, 2005; Willey et al., 2008). According 
to ICTV virus taxonomy list (2009), there are three families and 28 genera within the 
order Caudovirales. The tailed phage families are phylogenetically related and they are 
determined primarily on differences in tail structure, while genera are defined by genome 
structure and replication criteria (Ackermann, 2003; Kutter and Sulakvelidze, 2005; 
 22
Maniloff and Ackermann, 1998). Myoviridae, Siphoviridae, and Podoviridae comprise 
the three families in the order Caudovirales. Myoviridae consist of 25% of tailed phages, 
while Siphoviridae and Podoviridae make up 61% and 14%, respectively as determined 
by a study of frequency of phage morphologies in various environments (Ackermann, 
2001; Maniloff and Ackermann, 1998). Phages in family Myoviridae consist of 
contractile tails with two components, a sheath and a central tube (Ackermann, 2001). 
Phages in family Siphoviridae consist of long, non-contractile tails without sheath, and 
phages in family Podoviridae are similar to Siphoviridae except they have short, non-
contractile tails. The variations in tail morphology reflect major differences in viral 
genome complexity, mode of infection, and in virion assembly and maturation (Maniloff 
and Ackermann, 1998). The current tailed phage classification into genera is an ongoing 
process as more phages are being discovered and many unclassified phages are expected 
to be grouped in the future.  
 
1.9 Basic Phage Biology 
1.9.1 General Properties of Bacteriophages 
Similar to all viruses, bacteriophages are absolute parasites (Kutter and 
Sulakvelidze, 2005). They are able to reproduce quickly in susceptible hosts. At the same 
time, they are highly specific as each phage only targets a specific group of bacteria 
(Kutter and Sulakvelidze, 2005). Phages exist in two phases; extracellular and 
intracellular. They may contain a few enzymes and cannot reproduce independent of 
hosts in the extracellular phase, even though they possess all the required information to 
direct their own production (Kutter and Sulakvelidze, 2005; Willey et al., 2008). Most 
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phages remain infectious for a considerable period of time, even in the absence of a 
suitable host. During the intracellular phase, typical viruses simply induce host 
metabolism to synthesize viral components. Phage particles are assembled, with genome 
packaged inside the capsid, and released (Willey et al., 2008). 
Bacteriophages differ from most viruses as some phages possess the ability to 
integrate into host chromosome and remain as part of the bacterial genome. Based on this 
particular feature, bacteriophages can be categorized into two classes: virulent and 
temperate phages. Virulent, or strictly lytic phages, can only replicate during a lytic cycle 
(Kutter and Sulakvelidze, 2005; Willey et al., 2008). After phage DNA enters the host 
cell, virulent phages take over host metabolism and cellular machinery to execute the 
production of new phages. Following accumulation of assembled phage particles, the 
host cell lyses and releases a group of new phages into the surrounding environment. 
These new phage particles disperse and infect more bacteria.  
In contrast, temperate (sometimes mistakenly termed lysogenic) phages may 
initiate a lytic cycle or a lysogenic cycle (Clokie and Kropinski, 2009; Kutter and 
Sulakvelidze, 2005; Willey et al., 2008). When temperate phages enter the lysogenic 
cycle, the phage genome is integrated into the host genome (Freifelder and Meselson, 
1970) or sometimes maintained as a plasmid within the host cell (Ikeda and Tomizowa, 
1968; Inal and Karunakaran, 1996). A temperate phage in this condition is called a 
prophage (Clokie and Kropinski, 2009; Kutter and Sulakvelidze, 2005; Willey et al., 
2008). The prophage genome is replicated during cell division in the host, thus it can 
constitute part of the bacterial host genome indefinitely. These infected bacteria are 
called lysogens or lysogenic bacteria (Casjens, 2003; Clokie and Kropinski, 2009; Kutter 
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and Sulakvelidze, 2005; Willey et al., 2008). Virulent phages usually encode host-lethal 
proteins that affect host replication, transcription, or translation (Kutter and Sulakvelidze, 
2005). Host-lethal proteins are generally less common in temperate phages as 
restructuring of host metabolism may negatively impact long-term lysogeny (Kutter and 
Sulakvelidze, 2005).  
 
1.9.2 Lysogeny 
 Temperate phages have several distinctive properties due to their lysogenic 
nature. Lysogeny is common in bacterial populations (Weinbauer, 2004), and prophages 
or prophage-like sequences are important contributors to bacterial diversity and bacterial 
evolution (Brüssow et al., 2004; Casjens, 2003; Hendrix et al., 1999). They may 
significantly alter host properties including modifications to the restriction system, 
sensitivity to antimicrobials and other environmental selective pressures (Clokie and 
Kropinski, 2009; Kutter and Sulakvelidze, 2005). In addition, temperate phages provide 
host immunity from re-infection of the same phage or other phages (Casjens, 2003; 
Clokie and Kropinski, 2009; Kutter and Sulakvelidze, 2005; Willey et al., 2008). The 
phenotype of a bacterial host can also be changed by lysogenic conversions (Casjens, 
2003; Clokie and Kropinski, 2009; Willey et al., 2008). This change in cell phenotype 
may alter surface antigenic properties of the bacterium, or result in production of toxins 
due to virulence factors encoded by prophages (Canchaya et al., 2004; Casjens, 2003; 
Brüssow et al., 2004; Hendrix et al., 1999; Kutter and Sulakvelidze, 2005). The ability to 
enter the lysogenic cycle appears to be advantageous to phage in many cases. When 
bacteria become dormant due to nutrient deprivation, they stop synthesizing DNA or 
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proteins. Lysogeny allows temperate phages to enter a prophage state and survive within 
the host genome, whereas strictly lytic phages cannot undergo replication within a 
dormant host (Willey et al., 2008). In order to maintain lysogeny, temperate phages 
usually encode a repressor protein that blocks transcription of other phage genes such as 
the ones required during a lytic cycle (Clokie and Kropinski, 2009; Kutter and 
Sulakvelidze, 2005). Since this repressor protein may also exist in other phages, it may 
block lytic infection from these phages. If these phages regulate transcription with the 
same repressor protein, a temperate phage can provide host immunity to several different 
phages, all usually belonging to the same immunity group (Kutter and Sulakvelidze, 
2005). The term “prophage” was first used by Lwoff and Gutmann (1950) to describe the 
intracellular state of phage genomes. By treating lysogenic cells with appropriate agents 
such as ultraviolet light or chemical mutagens that damage host DNA, prophages can be 
induced to initiate a lytic cycle, a process called induction (Casjens, 2003; Clokie and 
Kropinski, 2009; Kutter and Sulakvelidze, 2005; Willey et al., 2008). Induction 
ultimately leads to destruction of the bacterial host cell and production of new virions.  
Even though most temperate phages have specific integration sites, there are cases 
where prophage DNA is excised erroneously along with adjacent fragments of bacterial 
host DNA (Kutter and Sulakvelidze, 2005). This may lead to specialized transduction 
resulting in a portion of host DNA next to the integration site being transferred to other 
bacterial cells, thereby altering their genomes. Generalized transduction also occurs with 
some phages, such as Mu, when they integrate randomly into the bacterial genome and 
naturally acquire host DNA during excision (Kutter and Sulakvelidze, 2005). Both 
temperate and virulent phages can produce generalized transduction by erroneously 
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packaging random fragments of bacterial host genome into capsids (Kutter and 
Sulakvelidze, 2005; Willey et al., 2008). Phage transduction may contribute significantly 
to bacterial evolution by exchanging pieces of bacterial information, or even introducing 
segments of genome into new organisms, either in lab or in nature (Briani et al., 2001; 
Kutter and Sulakvelidze, 2005). Prophage may account for genetic variability within a 
bacterial species through horizontal transfer of genetic information (Banks et al., 2002; 
Briani et al., 2001; Ohnishi et al., 2001). Prophage genomes may even carry genes that 
benefit the survival of bacteria in their ecological niche (Brüssow et al., 2004). 
 
1.9.3 Lysogeny of Phage λ 
 The conversion from a lytic to a lysogenic phase (or vice versa) has been well 
studied in phage λ (Casjens, 2003; Kutter and Sulakvelidze, 2005; Willey et al., 2008). It 
involves the control of several regulatory proteins binding to critical promoter regions. 
There are two closely associated promoter regions in phage λ, one responsible for 
lysogeny and other for lysis. A repressor protein, CI, binds to these sites to promote 
lysogeny and inhibits the lytic cycle by blocking transcription of most viral genes (Willey 
et al., 2008). However, there is another protein, Cro, which competes with CI and 
promotes the lytic cycle. Both CI and Cro proteins compete for binding sites in the 
complex promoter/operator region which inhibit transcriptions of counterparts and 
promote further transcription of its own gene. (Kutter and Sulakvelidze, 2005; Willey et 
al., 2008).  
 The CII and CIII proteins are also involved in binding to critical promoter regions. 
They stimulate transcription of cI gene and transition to a lysogenic state. Therefore, 
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depending on the levels of CI, CII, and CIII proteins, and the levels of Cro proteins, 
either the lysogenic or lytic cycle may prevail (Clokie and Kropinski, 2009; Willey et al., 
2008). CII proteins seem to be the key regulators during lysogeny (Kihara et al., 2001). 
Stability of CII protein is related to the host cell’s cyclic AMP (cAMP) level. The 
intracellular level of cAMP is high when the host cell is deficient in energy, a condition 
that stabilizes CII protein and promotes lysogeny. Other nutrient-associated factors such 
as protease levels may influence the activity of CII protein (Willey et al., 2008). CIII 
protein also protects CII protein from degradation (Willey et al., 2008). This repressor-
regulated system is advantageous for the phages as they can respond to different host cell 
conditions (Clokie and Kropinski, 2009; Kutter and Sulakvelidze, 2005; Willey et al., 
2008). If a cell is low in energy, phages can enter into a prophage state to ensure survival. 
Conversely, host cells with sufficient energy may enable phages to successfully replicate 
by undergoing a lytic cycle. Integration into the host chromosome is mediated by the 
phage enzyme integrase (Willey et al., 2008). Once inside the host cell, the linear phage λ 
genome is circularized when the two cohesive ends base pair with each other. There are 
homologous integration regions or attachment sites (att) in both the host chromosome and 
the phage genome (Willey et al., 2008), enabling the circular phage genome to form a 
linear stretch of DNA within the host genome. 
 Induction of prophages from the bacterial genome also correlate with the stability 
of the repressor protein mentioned earlier. When phage DNA is damaged due to 
induction, the activity of the RecA protein is changed due to induced SOS response from 
the host (Clokie and Kropinski, 2009; Kutter and Sulakvelidze, 2005). Usually, RecA 
proteins are crucial in recombination and DNA repair processes (Willey et al., 2008). In 
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this case, RecA protein interacts with repressor CI protein resulting in its self-degradation. 
This eventually leads to start of lytic cycle as CI repressor protein levels continue to 
decrease and Cro protein levels increase. As a result, the energetic state of the host cell 
has significant effects on the lysogenic and lytic states of the phage infection processes 
(Clokie and Kropinski, 2009). Although the conversion between lysogenic and lytic 
states is well described for phage λ it is largely uncharacterized for other phage types.   
 
1.10 Mechanism of phage infection/phage replication 
1.10.1 Infection Process 
 The study of phage reproduction by a one-step growth curve was first used by 
Ellis and Delbrück (1939). A one-step growth experiment allows researchers to determine 
the details of phage-host interactions and molecular events occurring during reproduction 
(Kutter and Sulakvelidze, 2005; Willey et al., 2008). To carry out this experiment, 
bacteriophage particles are mixed with appropriate bacterial host, and a short period of 
time is given for phage attachment. The mixture is then diluted to avoid any new virions 
from binding to uninfected cells. The diluted culture is then examined by plaque assay at 
various time points to determine the number of infectious phage particles released from 
the host bacterium (Kutter and Sulakvelidze, 2005; Willey et al., 2008). Using this 
strategy, several parameters such as the latent period, burst size, and eclipse period can be 
determined. Within a common bacterial host and with the same medium and temperature 
conditions, these parameters are distinctive for each phage strain (Kutter and 
Sulakvelidze, 2005). From studying a one-step curve, the entire phage infection process 
can be demonstrated. This involves a series of closely programmed events including 
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attachment to the host cell, penetration of the host cell, taking over host metabolism, and 
finally phage virion assembly and release. 
 
1.10.2 Adsorption/Penetration 
 Phage infection begins with virion binding to specific receptors on the host cell 
surface (Lindberg, 1973; Willey et al., 2008). Common receptors include cell wall 
lipopolysacharides and proteins, teichoic acids, flagella, and pili (Willey et al., 2008). As 
these receptors vary in each phage/host system, different adsorption mechanisms occur 
among phage-host relationships. For instance, T-even phage adsorption involves several 
tail structures binding to appropriate receptors on the cell surface of the host bacterium 
(Kutter and Sulakvelidze, 2005; Willey et al., 2008), prior to the baseplate settling on cell 
surface. Phage adsorption speed and efficiency are influenced by external factors and 
host physiological state. Many phages require divalent cations such as Ca2+ and Mg2+ as 
part of the binding process (Clokie and Kropinski, 2009; Kutter and Sulakvelidze, 2005; 
Willey et al., 2008). Mutation or alteration of receptors used by a phage can lead to 
bacteria developing resistance to phage, but this resistance offers no protection from 
other phages that recognize different cell surface receptors (Kutter and Sulakvelidze, 
2005). Moreover, phages like T4 have tail fibers that recognize multiple receptors (Tetart 
et al., 1998), making it more difficult for bacteria to develop resistance to these phage.  
 The mechanisms of phage DNA transfer into the host cell are also specific for 
each phage (Kutter and Sulakvelidze, 2005). Usually, phage tails contain some sort of 
enzymatic activity that penetrates the peptidoglycan layer. In the case of T-even phages, 
the baseplates have lysozyme activity that help the central tube penetrate the 
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peptidoglycan layer (Willey et al., 2008). Conformational changes with the baseplate and 
sheath also result in penetration through the cell wall. Once penetration occurs, linear 
phage DNA is transferred through the tail tube into the host cell. However, in a linear 
form phage DNA is subject to degradation by host exonucleases and restriction enzymes. 
Consequently, phages have developed various methods to structurally protect their 
genomes or to disable host nucleases. Circularization of phage DNA by cohesive ends or 
terminal repeats (Kutter and Sulakvelidze, 2005) is one means of reducing degradation of 
phage DNA from exonucleases. Other mechanisms include the production of host 
nuclease inhibitor proteins (Belogurov et al., 1993) or the presence of unusual nucleotides 
such as hydroxymethyldeoxycytidine in the T4 genome to avoid digestion (Warren, 
1980).  
 
1.10.3 Phage-Directed Metabolism 
 In order to synthesize viral nucleic acids and proteins, phages have to take over 
the host metabolism and cellular machinery. Although there are few exceptions, all 
double-stranded DNA viruses use a similar mechanism to generate viral DNA and 
synthesize viral proteins (Willey et al., 2008). The initial step involves interaction of host 
RNA polymerase with phage promoters resulting in the transcription of early phage genes. 
The produced early viral mRNAs are translated to produce several protein factors (e.g., 
antirestriction proteins) and enzymes (e.g., ADP-ribosyltransferases) that are crucial for 
phage genome protection and reprogramming of the host cellular machinery to 
manufacture viral components (Kutter and Sulakvelidze, 2005; Willey et al., 2008). 
Inactivation of host proteases and restriction enzymes protect phage DNA from being 
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degraded. Specific viral enzymes are synthesized to terminate host biosynthesis by 
degrading host proteins and DNA. A set of middle genes coding for DNA polymerase 
proteins and hydroxymethylase directs phage DNA synthesis, followed by another set of 
late genes that encode structural components (e.g., head, tail fiber, tail baseplate, etc.) of 
phage particles (Kutter and Sulakvelidze, 2005).  
 
1.10.4 Phage Particle Assembly/Cell Lysis 
 The assembly of most phages is an extremely complex process that requires 
specific viral proteins. These proteins include phage structural proteins, proteins that 
assist phage assembly, and proteins involved in host lysis (Willey et al., 2008). Phage 
DNA is packaged into phage proheads (procapsids) with the help of scaffolding proteins 
(Kutter and Sulakvelidze, 2005; Willey et al., 2008). A portal protein complex at the base 
of the prohead directs head assembly and DNA packaging, and serves as an attachment 
site for the separately assembled phage tail. For T4 phage, DNA packaging requires a set 
of terminase proteins that generate double-stranded ends of the concatemers produced 
during genome replication (Willey et al., 2008). Processed phage DNA then joins the 
portal protein complex for packaging into the capsid.  
 Two phage protein components are involved in host lysis by the tailed phages, 
lysin and holin (Kutter and Sulakvelidze, 2005; Willey et al., 2008). Lysin attacks the 
host’s cell wall by cleaving bonds in the peptidoglycan layer. Holin generates pores in the 
cytoplasmic membrane so lysin can reach the peptidoglycan matrix during this process. 
The timing of lysis is tightly regulated, but also affected by growth conditions and 
genetics of the phage (Kutter and Sulakvelidze, 2005). Early lysis may result in too few 
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phages being released to the environment or production of incomplete phage particles. In 
contrast, delayed lysis may limit the rate at which the phage can interact with and seek 
new hosts (Abedon, 1990). 
 
1.11 Phage Therapy 
1.11.1 Introduction 
 Due to the increased emergence and spread of antimicrobial resistant bacteria, 
there is a renewed interest in finding alternatives to the use of antimicrobials for treating 
bacterial infections (Clack and March, 2006; Johnson et al., 2008; Kutateladze and 
Adamia, 2010; Skurnik et al., 2007). Phage therapy is considered to be one feasible 
approach, by selecting and utilizing bacteriophages that specifically kill targeted 
pathogenic bacteria (Clack and March, 2006; Skurnik et al., 2007). Not long after their 
discovery, phages were frequently used as therapeutics to control bacterial infections in 
humans, particularly in Georgia, Russia, Poland and USA (Clack and March, 2006; 
Kutter and Sulakvelidze, 2005). The use of phage therapy diminished following the 
introduction of antimicrobials and its inconsistent efficacy in early research experiments 
(Clack and March, 2006; Johnson et al., 2008; Kutateladze and Adamia, 2010), but a 
resurged interest in bacteriophage therapy is occurring due to its potential effectiveness in 
treating serious infections caused by antimicrobial resistant pathogens (Kutter and 
Sulakvelidze, 2005; Willey et al., 2008). Phage therapy can be utilized in many areas, 
including treating bacterial infections in humans, animals, and plants, especially when 
chronic infections occur (Clack and March, 2006; Skurnik et al., 2007). It also helps in 
eliminating pathogenic bacteria in food and water, and reduces the use of antimicrobials 
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in agricultural production (Kutter and Sulakvelidze, 2005; Skurnik et al., 2007). The use 
of antimicrobials in agriculture contributes significantly to the rapidly growing burden of 
antimicrobial resistant bacteria and increases the risk of their entrance into the food chain 
(Skurnik et al., 2007). Typically, phages with relatively broad host range are more useful 
for therapeutic purposes as they have the capacity to infect multiple pathogens displaying 
common surface receptors (Johnson et al., 2008). For instance, two novel coliphages 
were found to lyse multiple serotypes of pathogenic groups of Escherichia coli, but few 
non-pathogenic strains (Vicardi et al., 2008).  
 The diversity of phages in nature provides an abundant supply of source material, 
and the knowledge gained from early phage research can be utilized to develop phages 
for therapeutic application. Phage therapy holds several advantages over antimicrobials. 
Due to the mechanism of infection and the specificity of bacteriophages, they are 
effective against multi-drug resistant pathogenic bacteria (Skurnik et al., 2007). The 
specificity of bacteriophages also reduces harmful effects on beneficial bacteria or 
commensal flora (Clack and March, 2006; Johnson et al., 2008; Kutateladze and Adamia, 
2010; Skurnik et al., 2007). Side-effects are rare since phages generally do not affect 
eukaryotic cells (Matsuzaki et al., 2005). The self-replicative nature of phages reduces 
the need for multiple doses as is often required for antimicrobials (Kutateladze and 
Adamia, 2010), and cost of developing a phage therapy is less than that of developing a 
new antimicrobial (Skurnik et al., 2007). Moreover, phage preparations can be modified 
in response to changes in bacterial pathogen population and susceptibility. Since the 
receptors on the cell wall are specific for different phages and it is almost impossible for 
the bacteria to mutate all receptors at once, use of a cocktail of phages can circumvent the 
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emergence of resistant bacteria (Kutateladze and Adamia, 2010). From early extensive 
use of phage therapy in humans, and from recent research studies in animals and humans, 
phages are generally considered safe (Johnson et al., 2008).  
 
1.11.2 Approach 
 Potential candidates for phage therapy should be thoroughly characterized (Gill 
and Hyman, 2010). For instance, phage genome sequence and structure should be 
determined and subject to bioinformatic analysis. Furthermore, research trials with 
rigorous testing and appropriate controls for the specific application should be conducted 
to confirm the efficacy of therapy (Carlton et al., 2005; Skurnik et al., 2007). Virulent 
phages are more suitable for phage therapy as they do not undergo lysogeny (Carlton et 
al., 2005; Goodridge, 2010; Skurnik et al., 2007). Temperate phages may elicit undesired 
phenotypical changes when they integrate into the host bacterial genome. For example, 
they may carry genes encoding virulence factors (Johnson et al., 2008; Kutateladze and 
Adamia, 2010; Skurnik et al., 2007) and transfer these genes to other bacteria through 
transduction (Johnson et al., 2008; Kutateladze and Adamia, 2010; Kutter and 
Sulakvelidze, 2005). Another undesirable trait of temperate phages is that they may 
replicate as prophages along with the host cell, without lysing the bacterial host (Johnson 
et al., 2008; Kutateladze and Adamia, 2010). Virulent phages, on the other hand, always 
enter a lytic cycle that results in degradation of host DNA, phage replication, lysis of host 
cell, and release of viable phage progeny (Kutter and Sulakvelidze, 2005).  
 
 35
1.11.3 Animal studies 
 Phage therapy has been discussed in various studies to control pathogenic 
bacterial infections in animals. It has been extensively used in veterinary medicine and in 
agricultural settings (Kutter and Sulakvelidze, 2005). For example, phages were used to 
control enterotoxigenic E. coli (ETEC) infections in neonatal calves, pigs, and lambs 
(Smith and Huggins, 1983; Smith et al., 1987). The mortality rate of phage-treated calves 
was significantly lower than the untreated control groups (Smith and Huggins, 1983). 
Although phages did not completely eliminate pathogenic E. coli, numbers were reduced 
to a level that limited the severity of disease. Moreover, phages persisted in the animal 
gut as long as pathogenic E. coli remained present. Similar challenge studies with 
enterotoxigenic strains of E. coli also demonstrated the efficacy of phage therapy on 
piglets and lambs (Smith and Huggins, 1983). Phage treatment was further evaluated with 
calves infected with pathogenic strains of E. coli in subsequent studies (Smith et al., 
1987). The results were promising as administration of phage quickly reduced E. coli to 
minimal levels in calves (Smith et al., 1987). Another challenge study used Salmonella-
infected chickens to study the therapeutic value of bacteriophages (Berchieri et al., 1991), 
and showed that the therapy significantly reduced their mortality. A study conducted by 
Barrow et al. (1998) used an E. coli-specific lytic phage to prevent septicemia and 
meningitis-like infection in chickens and calves. This study demonstrated that the 
efficacy of phage treatment in chickens was dose-dependent. The best protection was 
obtained with high doses of phage, prior to bacterial challenge. Phage treatment for 
calves orally challenged with pathogenic E. coli also produced a positive therapeutic 
effect. Aside from calves and chickens, other studies employed different bacterial 
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challenges to evaluate phage therapy in various animal models, such as Enterococcus 
faecium-infected mice (Biswas et al., 2002), Clostridium difficile-infected hamsters 
(Ramesh et al., 1999), and mice infected by Acinetobacter baumanii, Pseudomonas 
aeruginosa, and Staphylococcus aureus (Soothill, 1992). 
 
1.11.4 Phage Vaccines 
 Instead of using whole phage preparations as prophylactic or therapeutic 
treatments, one can also develop phage lysate-based vaccines to help reduce the use of 
antimicrobials in livestock animals. By reducing the incidence of bacterial infection, 
animal growth may be promoted, reducing the need for growth-promoting antimicrobials 
(Kutter and Sulakvelidze, 2005). One way to develop phage vaccines is to generate 
bacterial lysates using phage. Phage-induced bacterial lysates are very good immunizing 
agents and they elicit an immune response that is superior to conventional vaccines 
(Compton, 1928; Larkum, 1929; Weiss and Arnold, 1924). This is probably because 
conventional vaccine development usually generates antigens by inactivating pathogenic 
bacteria by heat, irradiation, or chemical treatment, processes which may damage 
relevant immunological epitopes and reduce vaccine effectiveness (Kutter and 
Sulakvelidze, 2005; Lauvau et al., 2001). Staphylococcus aureus phage lysate (SPL)® is a 
well known bacteriophage lysate generated using S. aureus-specific bacteriophages. The 
SPL vaccine was used in a mouse model to evaluate its efficacy in treating or preventing 
S. aureus infections (Esber et al., 1981), and the results were encouraging as SPL-treated 
mice had significantly higher survival rates than untreated controls. Similar to phage-
generated bacterial lysate, bacterial ghost vaccines can be constructed from phage-
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encoded bacteriolytic enzymes (Jalava et al., 2002; Kutter and Sulakvelidze, 2005; Mader 
et al., 1997; Panthel et al., 2003; Szostak et al., 1990; Szostak et al., 1996; Szostak et al., 
1997; Young, 1992). This was achieved by introducing the lysis gene e from 
bacteriophage φX174 into various Gram-negative bacteria using appropriate vectors. The 
vectors contain regulatory genes that allow tight repression and induction of the e gene 
(Jalava et al., 2002). Lysis protein E forms pores in the bacterial cell wall, resulting in a 
loss of cell contents (Schon et al, 1995; Witte et al., 1990). Because bacterial ghosts 
retain the majority of their outer membrane and immunostimulatory LPS endotoxin 
structure, they elicit an immune response similar to that of regular attenuated vaccines 
(Jalava et al., 2002; Witte et al., 1990). Various bacterial ghosts of Gram-negative 
bacteria have been prepared using this method, including E. coli (Blasi et al., 1985), 
Salmonella species (Szostak et al., 1996), Vibrio cholerae (Eko et al., 2003), and P. 
multocida and P. haemolytica (Marchart et al., 2003). In addition to designing ghost 
vaccines from phage lysis gene, phage encoded enzymes can be used as antibacterial 
agents (Fischetti, 2005). This concept has been supported in several studies. For example, 
the endolysin gene of S. aureus bacteriophage Twort was sequenced and cloned into E. 
coli JM109 to produce purified recombinant protein (Loessner et al., 1998). Endolysin 
may be an effective antimicrobial against S. aureus infection since it was shown to 
rapidly cleave staphylococcal peptidoglycan. Other studies have also shown that phage-
encoded lytic enzymes rapidly kill various pathogenic Gram-positive bacteria both in 
vitro and in vivo, while retaining host specificity (Loeffler et al., 2001; Nelson et al, 2001; 
Schuch et al., 2002). Moreover, these phage lysins seem to have the same degree of 
efficacy against antimicrobial-resistant bacteria (Loeffler et al., 2001; Nelson et al, 2001). 
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1.12 Bacteriophage in M. haemolytica 
 Bacteriophages were first isolated from M. haemolytica in the 1950s (Rifkind and 
Pickett, 1954; Saxena and Hoerlein, 1959). Pathogenic strains (serotype A1) of M. 
haemolytica have previously been shown to carry a prophage, which can be induced by 
DNA damaging elements (Richards et al., 1985). The isolated phage was named φPhaA1, 
and it was unable to form plaques on any of the A1 strains tested (Richards et al., 1985). 
As a result, the authors suspected that all tested strains harbored the same lysogenic 
bacteriophage (Richards et al., 1985), because temperate phage can provide host 
immunity against infection by other phages. Froshauer et al. (1996) also examined 14 
additional strains of M. haemolytica, isolated from cattle with shipping fever, and found 
that mitomycin C could be used to induce prophage excision from all 14 strains. In all 
cases, the phage DNA gave the same restriction enzyme digestion pattern, corresponding 
to a genome of about 40 kb. They concluded that all strains examined carried the same 
prophage and that this phage is widely distributed among M. haemolytica (Froshauer et 
al., 1996).  
 The M. haemolytica bacteriophages investigated by Davies and Lee (2006) had 
relatively diverse morphologies. All of the phages possessed icosahedral heads, but three 
different tail morphologies were present. Based on the results of the restriction 
endonuclease digest, they estimated the phage genomes ranged from 22 to 45 kb in size. 
The identification of nine distinct restriction profiles among the 24 phages induced also 
supports the idea that M haemolytica phages are relatively diverse. Another study by 
Highlander et al. (2006) revealed that among 16 strains of M. haemolytica, six of the 
strains (A1, A5, A6, A7, A8, and A13) were lysed following mitomycin C treatment, 
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suggesting that they contain temperate phages. Strains A1 and A6 are also two of the 
predominant serotypes isolated from bovine respiratory disease animals (Zecchinon et al., 
2005). 
 Based on the genome sequences of bovine M. haemolytica serotype A1 and A2, a 
considerable portion (12.3% and 11.5%) of the identified genes are bacteriophage-related 
(Gioia et al., 2006; Lawrence et al., 2010a). The M. haemolytica serotype A1 (strain 
BAA410) contained at least two intact prophages in the genome (Gioia et al., 2006). An 
intact P2-like phage, two Mu-like phages, and λ-like fragments were detected in the 
genome (Gioia et al., 2006). Typical P2-like phage and Mu-like phage are myoviruses, 
while λ is a siphovirus (Guttman et al., 2005). To date, the only M. haemolytica 
bacteriophage that has been sequenced completely is φMhaA1-PHL101. The prophage 
portion of this sequence was also determined and named φMhaA1-BAA410 (Highlander 
et al., 2006). This temperate bacteriophage was induced from M. haemolytica serotype 
A1 (strain PHL101), with a genome size of 34,525 bp (Highlander et al., 2006). It is a 
double-stranded DNA bacteriophage belonging to the P2 family of phages. The sequence 
of φMhaA1-PHL101 is very similar to the P2-like phage mentioned earlier from M. 
haemolytica strain BAA410, only 22 single-base-pair substitutions were observed 
between these two (Gioia et al., 2006).  
 The current methods for BRD prevention and treatment have various problems 
and limitations. Antimicrobial resistance has been reported in M. haemolytica. As a 
result, it is crucial to seek an alternative therapeutic strategy for this pathogen. 
Bacteriophage therapy presents a novel method to mitigate M. haemolytica. Several 
companies have already been working on therapeutic phage products to combat E. coli, 
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Salmonella typhimurium, Listeria monocytogenes, and Campylobacter jejuni in 
agricultural applications (Thiel, 2004). Feasibility of this approach depends on the 
isolation of a M. haemolytica-specific lytic bacteriophage from environmental sources. 
To date, no strictly lytic bacteriophages that are specific to M. haemolytica have been 
documented. Phages usually co-develop and share a common niche with their bacterial 
hosts (Brüssow and Kutter, 2005). They are highly abundant on earth (Kutter and 
Sulakvelidze, 2005; Willey et al., 2008). The total number is estimated at 1030 to 1032 
(Brüssow and Kutter, 2005), and it is expected that all bacteria are susceptible to 
infection by bacteriophages (Thiel, 2004). Lytic bacteriophages have been successfully 
isolated and shown promising results in treating bacterial infections in ruminants, 
including calves challenged with various enterotoxigenic strains of E. coli (Smith and 
Huggins, 1983; Smith et al., 1987), adult beef cattle challenged with E. coli O157:H7 
(Niu et al., 2008), and sheep challenged with E. coli O157:H7 (Callaway et al., 2008; 
Raya et al., 2006). An environmental source that contains the pathogen of interest is 
likely to contain phages capable of lysing that organism (Gill and Hyman, 2010). 
Therefore, bovine nasopharyngeal swabs were identified as the main source for isolating 
bacteriophages since M. haemolytica typically exists as a commensal organism in the 
upper respiratory tract in healthy ruminants (Catry et al., 2005; Highlander, 2001). 
Feedlot trough water is another possible phage reservoir as animals’ mouths are 
frequently in contact with it. Based on previous studies, a lytic bacteriophage capable of 
lysing Streptococcus suis was isolated from nasal swabs of healthy Bama minipigs (Ma 
and Lu, 2008), and a bacteriophage isolated from the waste water of sewer treatment 
plants or a poultry processing plant was found to be effective in controlling E. coli 
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respiratory disease in broiler chickens (Huff et al., 2003). These studies confirmed the 
practicality of isolating lytic bacteriophages from nasal swabs or water samples. The 
efficacy of an isolated bacteriophage will be determined against field strains of M. 
haemolytica and ultimately, it was proposed that a challenge study be conducted to 
determine if the selected phage was effective in reducing M. haemolytica in the 
respiratory tract of feedlot cattle. Although it is relatively easy to isolate novel 
bacteriophages from the environment, strictly lytic phages of some species of bacteria 
can be rare (Goodridge, 2010), and the presence of prophages within M. haemolytica 
genome (Gioia et al., 2006; Lawrence et al., 2010a) may also provide host immunity and 
prevent potential lytic bacteriophage from infecting M. haemolytica. Other factors such 
as bacterial restriction-modification systems, abortive infection mechanisms, or Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR) mechanisms may also affect 
bacteriophage infection (Gill and Hyman, 2010). As a result, we incorporate an extensive 
characterization of temperate bacteriophages induced from our M. haemolytica 
collection. Even though temperate bacteriophages are not the ideal candidates for phage 
therapy, they can be genetically engineered or modified to meet our requirement. Whole 
genome sequencing of selected temperate bacteriophages also provides a foundation for 
future phage vaccine development such as the phage-encoded lytic enzymes mentioned 
previously. The objectives of this study were to screen and isolate strictly-lytic or 
temperate bacteriophages specific to M. haemolytica. Isolated bacteriophages were 
characterized though various methods including electron microscopy, host range analysis, 
restriction fragment length polymorphism, and genome sequencing. The therapeutic 
potential of isolated bacteriophages was determined.  
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CHAPTER TWO 
Lytic bacteriophage(s) specific to Mannheimia haemolytica 
 
2.1 Introduction 
 Bovine respiratory disease often occurs when animals have impaired health or 
suppressed immune systems due to environmental or nutritional stress (Irsik, 2007). For 
example, viral infection or inhaled irritants can lead to cell damage in the upper 
respiratory tract (Irsik, 2007). This provides a window of opportunity for secondary 
pathogens such as M. haemolytica to colonize and reproduce quickly. M. haemolytica, a 
weakly haemolytic, Gram-negative coccobacillus, often shows up as a complicating agent 
in BRD (Zecchinon et al., 2005). Various researchers suggest M. haemolytica as the 
principle causative agent of BRD (Duff and Galyean, 2007; Gioia et al., 2006; Griffin et 
al., 2010; Zecchinon et al., 2005). Treatment of BRD linked to M. haemolytica usually 
entails prophylactic treatment with antimicrobials. However, to be effective, 
antimicrobials must be administered very early in the disease process (Irsik, 2007). 
Antimicrobial resistance is a major concern that needs to be monitored closely. M. 
haemolytica has shown increasing resistance to many antimicrobial agents (Watts et al., 
1994). Other means of mitigation such as vaccination against M. haemolytica also exist, 
but are less efficacious (Confer et al., 2006).  
 The potential for resistance to antimicrobials and the lack of comprehensive 
preventive measures against pathogenic M. haemolytica have made it important to seek 
alternative mitigation strategies. Bacteriophage therapy presents an innovative area of 
research for preventing bacterial infections. Bacteriophages are a group of viruses that 
can infect, replicate, and cause lyses of specific bacteria (Clark and March, 2006). Phage 
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therapy provides a number of advantages over the use of antimicrobials. For instance, 
phages are effective in treating multidrug-resistant bacterial infections (Skurnik et al., 
2007). Phages possess host-specificity, which means they are less likely to harm 
commensal bacterial flora in animals (Clack and March, 2006; Johnson et al., 2008; 
Kutateladze and Adamia, 2010; Skurnik et al, 2007). Moreover, phages can self replicate, 
reducing the need for multiple doses, as required in antimicrobial therapy (Kutateladze 
and Adamia, 2010; Skurnik et al., 2007). 
Several studies have investigated the use of lytic phage therapy against bacterial 
pathogens. For example, inoculation of broiler chickens with bacteriophage significantly 
reduced mortality during E. coli challenge experiment (Huff et al, 2003). Temperate 
phages specific to M. haemolytica have been isolated and characterized (Davies and Lee, 
2006; Highlander et al, 2006). Temperate phages do not lyse host cells consistently and 
possess a transducing capability with the host genome (Johnson et al., 2008; Kutateladze 
and Adamia, 2010; Kutter and Sulakvelidze, 2005; Skurnik et al., 2007). Transduction 
may cause undesired phenotypic changes to a recipient bacterium when temperate phages 
carry and integrate genes encoding virulence factors from previously infected cells during 
lysogenization (Adam, 1959). Usually, this type of bacteriophage is not suitable as a 
direct therapeutic. In this study, we attempted to isolate one or more strictly lytic phage(s) 
with activity against M. haemolytica. Strictly lytic (virulent) phages will always enter 
their lytic cycle and kill the bacterial host (Kutter and Sulakvelidze, 2005). Depending on 
the number of lytic phages isolated, desired phages will be further characterized. The 
activity of acquired lytic phage will be assessed against a large collection of M. 
haemolytica that have been isolated from commercial feedlot cattle. Phages that possess 
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strong lytic activity and broad host range will be used in further animal studies to control 
M. haemolytica infection. 
 
2.2 Materials and methods 
Bacterial Isolates 
Three M. haemolytica reference strains and six M. haemolytica field strains were 
used to enrich lytic bacteriophage isolated from cattle. Strains of M. haemolytica used in 
this study are listed in Table 2.1. Isolates were stored at -80°C in 20% (v/v) glycerol in 
brain heart infusion broth (BHIB). Single colonies of M. haemolytica were obtained by 
streaking on tryptic soy agar (TSA) plates containing 5% sheep blood (v/v) (Dalynn 
Biologicals, Inc., Calgary, AB, Canada) and incubated overnight at 37 °C. Starter 
cultures were prepared by inoculating 10 mL of fresh BHIB with single colonies of each 
isolate. The cultures were incubated at 37 °C overnight with shaking at 120 rpm.  
 
Table 2.1. Properties of three M. haemolytica reference strains and six M. haemolytica 
field strains used for phage enrichment. 
Strain Source Serotype 
BAA-410 ATCC A1 
33396 ATCC 2 
33370 ATCC 6 
413A feedlot 5, arrival  2 
501A feedlot 5, arrival  1 
535A feedlot 21, arrival  1 
964A feedlot 21, arrival  6 
1098A feedlot 21, exit 2 
1498A feedlot 5, exit 2 
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Sample preparation  
A total of 689 bovine nasopharyngeal swabs were obtained from four regional 
feedlots (Table 2.2). Samples were chosen randomly from M. haemolytic-positive and M. 
haemolytic-negative swabs received each week. Swabs were submerged and vortexed in 
BHI broth containing 20% glycerol. Either individual or pooled nasopharyngeal swab 
suspensions were filtered through 0.8/0.2-μm-pore size low protein binding syringe filters 
(Pall Canada Ltd., Mississauga, ON). In addition, 30 pooled water samples (500 mL) 
were obtained from the Lethbridge Research Centre feedlot water troughs and filtered 
through 0.2-μm-pore size bottle top filter (Nalgene, Fisher Scientific, Ltd. (Canada), 
Nepean, ON). Water filtrates (15 mL) were concentrated by Centriprep YM-30 
centrifugal filter units (Millipore, Billerica, MA, USA) at 1,500 × g for 15 min at room 
temperature, to a final volume of 3 to 5 mL before further processing. 
 
Table 2.2. Bovine nasopharyngeal swabs examined in this study. 
Feedlot  
Number of arrival 
samples 
Number of exit 
samples 
Total number of 
samples 
#5 59 93 152 
#21 63 79 142 
#31 125 89 214 
#42 97 84 181 
 
 
Enrichment 
The basic enrichment protocol was described by Carlson (2005). Briefly, two 
separate M. haemolytica enrichment cocktails were prepared using a mix of reference 
strains (BAA-410, 33396, 33370) and a mix of field isolates (413A, 501A, 535A, 964A, 
1098A, 1498A). These strains were intentionally selected to represent the dominant 
 46
pathogenic and non-pathogenic serotypes of M. haemolytica, and broadly representative 
of our collection of M. haemolytica field strains. Cocktails of early-log M. haemolytica 
liquid culture (5 mL; approximately 5 × 108 CFU/mL) were combined with 1 mL of the 
nasopharyngeal swab filtrate or water filtrate, and 50 μL filter-sterilized MgSO4 (1M) 
solution. The mixture was incubated for 18-20 h at 37° C with shaking at 150 rpm, and 
filtered through 0.8/0.2-μm-pore size filter. Different ratios (1:1, 5:1, 10:1) of M. 
haemolytica cocktail to sample filtrate were tested. 
 
Detection 
The double agar overlay method was used for bacteriophage detection. M. 
haemolytica strains listed in Table 2.1 were used as indicator strains. Each enriched 
filtrate (500 µL) was mixed with either individual or cocktails of M. haemolytica liquid 
cultures (500 µL) at early-log phase. The mixture was incubated for 15-20 min at room 
temperature to allow bacteriophage attachment. Molten agar (2 mL) (top agar) was added 
to the mixture and poured on to agar plates (bottom agar). Poured agar plates were 
allowed to set at room temperature for 20-30 min. Agar plates were inverted and 
incubated at 37 °C for 18-20 h and examined for plaque formation. Various combinations 
of agar, agar concentration, and divalent ion supplement were used in the double agar 
overlay procedure. This included modified nutrient agar (MNA), BHI agar, and modified 
BHI agar as bottom agar. UltraPureTM agarose (Invitrogen Canada Inc., Burlington, ON), 
Difco™ Agar (BD Canada, Inc., Mississauga, ON) and BHI agar were prepared with 
concentrations ranging from 0.4% to 0.7% to serve as top agar. Either top agar or bottom 
agar was supplemented with 5mM CaCl2 or 10mM MgSO4 divalent ions. Combinations 
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of the above media were first tested on identical samples wherever possible. If M. 
haemolytica cultures grew well with a particular media combination, it was adapted in 
bacteriophage detection. Approximately 50% of the detection assays utilized 0.7% 
Difco™ top agar containing 10mM MgSO4 and regular BHI as bottom agar.  
 
2.3 Results and discussion 
A comprehensive screening process was undertaken in an attempt to isolate 
strictly lytic bacteriophage(s) specific to M. haemolytica. In principle, any environmental 
source that contains the target pathogen is likely to contain phages capable of lysing that 
organism (Gill and Hyman, 2010). Bovine nasopharyngeal swabs and feedlot trough 
water were identified as potential niches harboring specific phages. Previous studies have 
found bacteriophages specific to Streptococcus suis in nasal swabs (Ma and Lu, 2008) 
and to Salmonella Enteritidis, E. coli, and Enterococcus faecalis in water sources 
(Higgins et al., 2005; Huff, 2003; Uchiyama et al., 2008). Among these pathogens, S. suis 
and E. coli are involved in respiratory tract infections in pig and chicken, respectively. 
Nasopharyngeal swabs were the main focus in this study since M. haemolytica typically 
exists as a commensal organism in the upper respiratory tract in healthy ruminants (Catry 
et al., 2005; Highlander, 2001). Nasopharyngeal swabs were randomly selected each 
week from both M. haemolytica positive and M. haemolytica negative samples. 
Depending on the number of samples received, three to eight (usually five) swab 
suspensions were pooled to generate larger processing volumes and increase the 
probability of phage detection. The enrichment step was a method used to facilitate 
isolation of particularly virulent, broad-spectrum phages that may be present at low levels 
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in the sample (Carlson, 2005; Gill and Hyman, 2010; Jensen et al., 1998). Pooling of 
multiple samples allowed us to select desirable phages from a larger and potentially more 
diverse population of phages (Gill and Hyman, 2010). Cocktails of M. haemolytica were 
prepared by deliberately selecting reference strains and field strains that represent 
dominant pathogenic and non-pathogenic serotypes of M. haemolytica. Serotype 2 is the 
predominant serotype isolated from healthy cattle (Hodgins and Shewen, 2004b), 
whereas serotype 1 and serotype 6 are most frequently isolated from cattle with BRD 
(Griffin et al., 2010; Hodgins and Shewen, 2004b). The field strains were also selected to 
encompass the genetic diversity of M. haemolytica based on PFGE analysis of greater 
than 400 field isolates from the Lethbridge Research Centre collection (Klima et al., 
2011). To increase the geographical and chronological representation of enrichment 
strains, isolates originating from different feedlots and separate sampling events were 
selected. A total of 689 bovine nasopharyngeal swabs (Table 2.2) and 30 pooled water 
samples were collected and screened for the presence of lytic bacteriophage(s) against M. 
haemolytica. In spite of rigorous screening effort and extensive adjustment in enrichment 
protocols, growth media, and phage detection assays, no lytic bacteriophage(s) specific to 
M. haemolytica were detected from either source.  
This section explains several potential difficulties that may have led to the 
inability to isolate M. haemolytica-specific lytic bacteriophage(s) in this study. The 
number of M. haemolytica-specific lytic bacteriophage(s) may be too scarce in the 
locations tested; transportation and processing of raw samples may have further reduced 
phage count and viability. Even though nasopharyngeal swabs have been used as a 
noninvasive diagnostic method for respiratory infections in cattle harbouring M. 
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haemolytica, evaluation of this method for representative viral entities has not been 
conducted (Cooper and Brodersen, 2010). The process of concentrating water samples 
may also hinder phage carriage or survival (Gill and Hyman, 2010), possibly due to 
incomplete phage filtration or phage particle damage introduced by centrifugal forces. 
Binding to non-target particles within water of nasal samples is also a possibility. Biases 
introduced by enrichment and plating methods may affect desirable phage detection 
because enrichment could cause a single rapidly replicating phage to dominate entire 
culture while masking other potential phages and not all phages are efficient plaque 
formers under typical plating conditions (Gill and Hyman, 2010). For instance, a 
particularly virulent phage isolated during enrichment may be undetected in double agar 
overlay plaque assay, but still possesses high lytic activity in vivo.  
Often phages require specific cofactors or divalent ions, such as Ca2+ or Mg 2+, 
during the infection process (Clokie and Kropinski, 2009; Kutter and Sulakvelidze, 2005; 
Willey et al., 2008), thus these ions were supplied in our detection method. Nevertheless, 
they may not fulfill specific nutrient or mineral requirements of an uncharacterized 
phage. In the end, the number of viable bacteriophage(s) may be too low that even after 
enrichment procedure they remain undetected. A more sensitive molecular screening 
method may be a feasible approach in this situation.  
Temperate bacteriophages are widespread in bovine and ovine M. haemolytica 
isolates (Davies and Lee, 2006). During lysogeny, they provide host immunity from re-
infection of the same phage or other phages (Casjens, 2003; Clokie and Kropinski, 2009; 
Hyman and Abedon, 2010; Kutter and Sulakvelidze, 2005). In order to persist in a 
bacterial genome, temperate phage usually encodes repressor proteins that block 
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transcription of other phage genes such as the ones required during lytic cycle (Willey et 
al., 2008). As a result, repressor proteins may inhibit reproduction of lytic bacteriophages 
specific to M. haemolytica. 
Naturally, bacteria utilize various innate phage-resistance mechanisms to ensure 
survival under the pressure of phage infection. This includes mechanisms such as DNA 
modification, abortive infection, and phage adsorption resistance (Hyman and Abedon, 
2010; Sturino and Klaenhammer, 2006). Various studies suggest clustered regularly 
interspaced short palindromic repeats (CRISPR) and CRISPR-associated sequence (CAS) 
proteins are linked to a novel mechanism of acquired resistance against bacteriophages 
(Barrangou et al., 2007; Deveau et al., 2008; Hyman and Abedon, 2010; Mojica et al., 
2009; Sorek et al., 2008). The CRISPR array was first discovered in E. coli (Ishino et al., 
1987), and subsequent studies by Barrangou and colleagues confirmed its function 
experimentally (Barrangou et al., 2007; Deveau et al., 2008; Horvath et al., 2008). In 
response to phage infection, bacteria can integrate new spacers that are derived from 
phage genomic sequences, which results in CRISPR-mediated phage resistance 
(Barrangou et al., 2007). Moreover, the number and type of the spacers between CRISPR 
repeats are linked to phage sensitivity (Barrangou et al., 2007; Lawrence et al., 2010b). 
Although the exact mechanism by which CRISPR systems work is still unclear, some 
suggest that CRISPR functions by an RNA-silencing (RNA interference)-like mechanism 
(Makarova et al., 2006; Mojica et al., 2005; Sorek et al., 2008). The CRISPR system is 
widespread in the genomes of many bacteria (Mojica et al., 2009; Sorek et al., 2008), 
which implies its effectiveness in providing protection against phage attacks. 
Interestingly, a recent study indicates that CRISPR regions are also present in the M. 
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haemolytica genomes (Lawrence et al., 2010b). CRISPR/Cas loci were identified in all 
three M. haemolytica isolates examined (Lawrence et al., 2010b). This suggests CRISPR 
assays are common in M. haemolytica and their presence may indeed provide immunity 
to bacteriophages. This could have resulted in our inability to detect or isolate lytic 
bacteriphages specific to M. haemolytica. 
Since our samplings were restricted to deep nasopharyngeal swabs, swabs taken 
from other areas of the respiratory tract or even lung tissues of morbid animals may be 
worth exploring. Molecular screening methods that utilize phage sequences and PCR 
technique may offer a more sensitive approach for identifying candidate phage, as one 
may design primers from sequences of closely related bacteriophages. Temperate 
bacteriophages of M. haemolytica may also have therapeutic potentials, especially with 
functional components such as lytic enzymes (Fischetti, 2005; Loessner et al., 1998). 
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CHAPTER THREE 
Characterization of temperate bacteriophages induced from bovine Mannheimia 
haemolytica isolates. 
 
3.1 Introduction 
 Mannheimia haemolytica, previously known as Pasteurella haemolytica, is a 
Gram-negative bacterium and a principal agent associated with bovine respiratory disease 
(BRD) or  shipping fever (Duff and Galyean, 2007; Gioia et al., 2006; Griffin et al., 
2010; Zecchinon et al., 2005). The morbidity and mortality associated with BRD have 
significant economic impact on the feedlot industry (Duff and Galyean, 2007; Edwards, 
1996). Mortality from BRD and the expenses of preventative and prophylactic treatment 
contribute to its impact on the feedlot industry. Feedlot performance and carcass quality 
are also compromised by BRD (Duff and Galyean, 2007; Gardner et al., 1999). There are 
12 capsular serotypes of M. haemolytica - A1, A2, A5, A6, A7, A8, A9, A12, A13, A14, 
A16, and A17 (Fulton, 2009; Katsuda et al., 2007; Srikumaran et al., 2007). The 
organism normally exists as a commensal in the upper respiratory tract of healthy 
ruminants (Highlander, 2001), but genetically distinct subpopulations which may elicit 
disease also exist (Davies et al., 1997). While serotype 2 is the predominant serotype of 
M. haemolytica isolated from healthy cattle (Hodgins and Shewen, 2004b), serotypes 1 
and 6 are most commonly isolated from cattle with BRD (Griffin et al., 2010; Hodgins 
and Shewen, 2004b; Zecchinon et al., 2005). 
 As agents of lateral gene transfer, bacteriophages contribute significantly to the 
variability and the consequential evolution of bacterial genomes (Canchaya et al., 2003a; 
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Davies and Lee, 2006). However, this evolutionary process also applies to genes that 
code for virulence factors that can confer pathogenicity to their bacterial host (Willey et 
al., 2008). Horizontal DNA transfer has previously been implicated in the evolution of M. 
haemolytica lktA and ompA genes and the emergence of new strains (Davies et al., 2001; 
Davies et al., 2002). Bacteriophages were first isolated from M. haemolytica in the 1950s 
(Rifkind and Pickett, 1954; Saxena and Hoerlein, 1959). Later, a phage designated 
φPhaA1 was isolated from M. haemolytica biotype A, serotype 1 (A1). As this phage was 
unable to form plaques on any of the A1 strains tested; it was suggested that all strains of 
this serotype harbored the same temperate bacteriophage (Richards et al., 1985). 
Froshauer et al. (1996) examined 14 strains of M. haemolytica isolated from cattle with 
shipping fever, and found all strains carried a ~40 kb prophage. A study by Highlander et 
al. (2006) revealed that six strains (A1, A5, A6, A7, A8, and A13) of M. haemolytica 
lysed after exposure to mitomycin C, an inducing agent that can promote the excision of 
prophages from the bacterial genome. Davies and Lee (2006) investigated temperate 
bacteriophages from 15 bovine and 17 ovine M. haemolytica isolates, with genome sizes 
ranging from of 22 to 45 kb.  
 Froshauer et al. (1996) demonstrated that danofloxacin, a fluoroquinolone with 
broad spectrum antibacterial activity, causes DNA damage in M. haemolytica. This 
damage induces prophage in M. haemolytica to undergo the lytic cycle and leads to cell 
lysis. It was discovered that the degree of prophage induction is related to total exposure 
of bacteria to the antimicrobial compound. The authors concluded that the presence of an 
inducible prophage increases the sensitivity of M. haemolytica to danofloxacin 
(Froshauer et al., 1996). 
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 The objective of this study was to extend previous research on M. haemolytica 
phage by screening a diverse collection of bovine M. haemolytica isolates for temperate 
bacteriophages. The M. haemolytica isolates have been characterized extensively in terms 
of genetic diversity and antimicrobial susceptibility (Klima et al., 2011). Based upon 
previous reports in the literature, I hypothesized that temperate bacteriophages would be 
prevalent and diverse in our M. haemolytica culture collection. Mitomycin C treatment 
was used to induce prophages in the M. haemolytica isolates and the diversity of isolated 
bacteriophage particles was determined by comparing virion morphology, host 
specificity, restriction fragment length polymorphisms and genomic sequences. This 
study also determined that enrofloxacin, a typical fluoroquinolone antimicrobial 
administered to cattle, did not provide similar effect to that of danofloxacin, where the 
presence of an inducible prophage in M. haemolytica correlated positively to its 
antimicrobial resistance. These results suggest that M. haemolytica isolates with higher 
enrofloxacin susceptibility are not more likely to contain inducible phages.  
 
3.2 Materials and methods 
Bacterial strains 
 A total of 82 M. haemolytica isolates were examined in this study (Table 3.1). 
Ten reference strains were obtained from the American Type Culture Collection (ATCC, 
Manassas, VA, USA) and University of Guelph culture collection (UGCC, Guelph, ON, 
Canada). Field strains of M. haemolytica were isolated from bovine nasopharyngeal 
swabs collected from feedlot cattle in southern Alberta, Canada. Identification of M. 
haemolytica isolates was confirmed by multiplex polymerase chain reaction (Alexander 
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et al., 2008). Isolates were stored at -80°C in brain heart infusion broth (BHIB) 
containing 20% (v/v) glycerol. A total of 72 M. haemolytica field strains, representing 
each of the three serotypes detected (serotypes 1, 2, and 6), were selected from isolates 
collected from cattle at either arrival or > 60 days on feed at four regional feedlots. Single 
colonies of M. haemolytica isolates were obtained by streaking cells on tryptic soy agar 
(TSA) plates containing 5% sheep blood (v/v) (Dalynn Biologicals, Inc., Calgary, AB, 
Canada). The inoculated plates were incubated overnight at 37 °C. Starter cultures were 
prepared by inoculating 10 mL of fresh BHIB with single colonies of each isolate and 
incubated overnight at 37 °C with shaking at 120 rpm. A preliminary M. haemolytica 
growth curve analysis was carried out to determine inoculation and incubation conditions 
necessary to obtain early-log cultures for phage induction and plating procedures. 
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Table 3.1. Properties of 10 M. haemolytica reference strains and 72 M. haemolytica field 
isolates. 
Reference Strains 
Isolate Serotype Source 
ENRO 
ZD 
(mm)1
 Phage 
morphology 
Bacterial 
PFGE 
Type2
Phage 
RFLP 
Type3
BAA410 1 ATCC  N/A Myoviridae/ Siphoviridae4 N/A
5 N/A 
G1 1 Geulph N/A Undetected N/A N/A 
G2 2 Geulph N/A Undetected N/A N/A 
G5 5 Geulph N/A Undetected N/A N/A 
33370 6 ATCC  N/A Undetected N/A N/A 
29698 7 ATCC  N/A Undetected N/A N/A 
G8 8 Guelph  N/A Myoviridae/ Siphoviridae N/A N/A 
29700 9 ATCC  N/A Undetected N/A N/A 
G12 12 Guelph  N/A Undetected N/A N/A 
G14 14 Guelph  N/A Undetected N/A N/A 
        
Field Strains 
Isolate Serotype Feedlot information 
ENRO 
ZD 
(mm) 
 Phage 
morphology 
Bacterial 
PFGE 
Type 
Phage 
RFLP 
Type 
25A N/A 21 Arrival 36 Myoviridae N/A 11 
140A 2 21 Arrival 35 Siphoviridae B 9 
143A 2 21 Arrival 26 Siphoviridae A 5 
251B 2 21 Arrival 37 Siphoviridae A 8 
254A 2 21 Arrival 36 Siphoviridae A 8 
309A 2 21 Arrival 26 Siphoviridae A 6 
369A 2 5 Arrival 25 Undetected N/A N/A 
394A 2 5 Arrival 25 Undetected N/A N/A 
407A 2 21 Arrival 26 Siphoviridae C 8 
410A 2 5 Arrival 25 Siphoviridae A 14 
413A 2 5 Arrival 34 Myoviridae A N/A 
501A 1 5 Arrival 32 Siphoviridae F 7 
535A 1 21 Arrival 25 Siphoviridae G 7 
587A 2 21 Exit 38 Myoviridae A 5 
611A 1 5 Exit 26 Siphoviridae H 12 
613A 2 21 Exit 36 Myoviridae/ Siphoviridae A N/A 
622A 2 21 Exit 36 Myoviridae/ Siphoviridae C N/A 
755A 2 5 Arrival 36 Myoviridae A 1 
813A 2 21 Exit 35 Undetected N/A N/A 
842A 2 21 Arrival 35 Myoviridae A 13 
863A 2 21 Arrival 36 Undetected N/A N/A 
882A 2 21 Exit 26 Undetected N/A N/A 
925A 2 21 Exit 35 Undetected N/A N/A 
940A 2 5 Exit 38 Undetected N/A N/A 
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946A 2 5 Exit 34 Siphoviridae B N/A 
964A 6 21 Arrival 32 Myoviridae H N/A 
1040A 2 21 Exit 36 Myoviridae A 5 
1059A 2 5 Exit 25 Myoviridae A 5 
1098A 2 21 Exit 30 Siphoviridae C N/A 
1127A 2 21 Exit 25 Myoviridae B 3 
1152A 6 21 Exit 25 Myoviridae H 7 
1312A 2 5 Exit 25 Myoviridae A 10 
1316A 2 5 Exit 25 Undetected N/A N/A 
1391A 2 5 Exit 26 Undetected N/A N/A 
1492A 2 5 Exit 35 Myoviridae A 5 
1498A 2 5 Exit 31 Myoviridae B 5 
1719A 2 21 Exit 25 Myoviridae A N/A 
1731A 1 21 Exit 25 Undetected N/A N/A 
1745A 2 5 Exit 26 Myoviridae A 5 
1795A 2 21 Exit 26 Myoviridae/ Siphoviridae A N/A 
1829A 2 5 Exit 26 Siphoviridae A 8 
2024A 2 21 Exit 26 Myoviridae/ Siphoviridae E N/A 
2237A 1 5 Arrival 25 Myoviridae H 7 
2256A 1 5 Arrival 25 Siphoviridae H 7 
2259A 1 5 Arrival 25 Undetected N/A N/A 
2318A 2 21 Arrival 25 Myoviridae H 7 
2657A 2 5 Arrival 35 Siphoviridae I N/A 
2673B 2 5 Arrival 39 Siphoviridae I N/A 
2677A 2 5 Arrival 35 Myoviridae A N/A 
2679A 2 5 Arrival 35 Myoviridae I N/A 
2707A 2 5 Arrival 45 Myoviridae A N/A 
2713A N/A 5 Arrival 25 Siphoviridae F N/A 
2791A 1 21 Exit 25 Myoviridae H 5 
3083A 6 5 Exit 25 Myoviridae F N/A 
3089A 6 5 Exit 26 Siphoviridae H N/A 
3672A 1 21 Exit 26 Undetected N/A N/A 
3674A 1 21 Exit 25 Undetected N/A N/A 
3721A 2 21 Exit 35 Myoviridae I 5 
3724A 2 21 Exit 35 Myoviridae A 8 
3728A 2 21 Exit 35 Undetected N/A N/A 
3911A 2 5 Exit 35 Myoviridae D 5 
3927A 6 5 Exit 24 Myoviridae D 4 
3931A 2 5 Exit 26 Undetected N/A N/A 
4031A 2 21 Exit 37 Undetected N/A N/A 
4386A 2 21 Exit 36 Siphoviridae C 5 
4387A 2 21 Exit 35 Myoviridae C 5 
4645A 2 21 Exit 35 Siphoviridae C 6 
4653A 2 21 Exit 35 Siphoviridae I N/A 
4661A 2 21 Exit 36 Undetected N/A N/A 
4664A 2 21 Exit 37 Myoviridae A 2 
5039A 2 5 Exit 35 Myoviridae A N/A 
5042A 2 5 Exit 36 Undetected N/A N/A 
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1 ENRO ZD: Enrofloxacin inhibition zone diameter in millimeter (mm). 
2 Bacterial PFGE Type: Type A - Type I based on ≥65% similarity cut-off (relatedness). 
3 Phage RFLP Type: Type 1 - Type 14 based on ≥70% similarity cut-off (relatedness). 
4 Myoviridae/Siphoviridae: Both Myoviridae and Siphoviridae morphologies were detected. 
5 N/A: Not applicable. 
 
Bacteriophage isolation 
 Bacteriophages were induced from M. haemolytica isolates using a modification 
of the procedure by Davies and Lee (2006). Briefly, fresh 30 mL of BHIB was inoculated 
with an appropriate volume (0.3-1.0 mL) of overnight liquid starter culture of each isolate 
and incubated at 37°C with shaking at 120 rpm. Each culture was incubated for 3-6 h to 
achieve early-log phase (approximately 5 × 108 CFU/mL). Phage induction was initiated 
by adding freshly prepared mitomycin C (Sigma-Aldrich Canada Ltd., Oakville, ON) 
solution to each culture to a final concentration of 0.2 μg/mL. Optical density (OD660nm) 
of the induced culture was monitored for 7-8 h. Induced M. haemolytica cultures were 
centrifuged at 3,000 × g for 20 min at 4°C and filtered through 0.22 μm Steriflip-GP filter 
units (Millipore, Billerica, MA) to remove bacterial debris. Bacteriophage filtrates were 
stored at 4°C until further characterized. 
 
Enrofloxacin hypothesis 
 A total of 66 M. haemolytica isolates were used in a chi-square test to determine 
statistical association between enrofloxacin susceptibility of M. haemolytica isolates and 
the presence of inducible bacteriophages. Two groups (n = 33) of M. haemolytica isolates 
with either intermediate susceptibility (inhibition zone diameter 24-26 mm) or high 
susceptibility (inhibition zone diameter 35-45mm) were examined. Enrofloxacin 
susceptibility was determined by disk diffusion assay (Klima et al., 2011). A chi-square 
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value was generated by the FREQ of SAS program (SAS Institute Inc., Cary, NC). 
Associations were considered statistically significant if P ≤ 0.05.  
 
Host range analysis 
 A plaque assay (spot test) was used to determine host range of the induced 
bacteriophages (Davies and Lee, 2006). Lawns of M. haemolytica indicator strains 
(consisted of 10 individual reference strains and 70 individual field strains listed in Table 
3.1) were prepared by mixing 1 mL of overnight liquid cultures with 2 mL of molten agar 
(0.7% agarose in BHIB; BD Canada, Inc., Mississauga, ON) supplemented with 2 mM 
CaCl2, and poured onto regular BHI agar plates. After the top agar solidified, 10 μL of 
each phage filtrate was spotted and absorbed onto prepared agar plates. Plates were 
incubated upright overnight at 37°C and examined for clearing zones. Eight selected 
phage filtrates and eighty M. haemolytica indicator strains were used for this analysis. In 
order to confirm the zones of clearing were not due to growth inhibitory effect of 
bacteriocins, 10 μL of M. haemolytica cultures (identical strains used for phage 
induction) were spotted onto lawns of M. haemolytica indicator strains and examined for 
zones of growth inhibition. 
 
Electron microscopy 
  Morphological examination of bacteriophage using transmission electron 
microscope (TEM) was performed as described by Carlson (2005). Briefly, 30 mL of 
phage filtrate was centrifuged in a fixed-angle rotor at 25,000 × g for 90 min to sediment 
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phage particles. Supernatants were carefully removed and phage pellets were 
resuspended in sterile 0.1M ammonium acetate buffer (pH 7.0). This washing process 
was repeated a second time to remove proteins, sugars, and salt. Final phage pellets were 
resuspended in 250 μL of 0.1M ammonium acetate buffer. One drop of the phage 
suspension was absorbed onto a carbon-coated 200 mesh copper grid (Canemco, Inc., 
Canton de Gore, QC). Phage samples were negatively stained with 5% uranyl acetate 
solution (pH 4.0) for approximately 1 min. Excess stain was removed with filter paper 
and grids were examined by TEM (Hitachi H7100: Hitachi High-Technologies Canada, 
Inc., Toronto, ON) at 75.0 kV and a magnification range of 20,000× to 100,000×.  
 
Restriction fragment length polymorphism (RFLP) analysis 
 Genomic bacteriophage DNA was extracted and purified from concentrated phage 
suspensions using a Phage DNA Isolation kit (product # 26100, Norgen Biotek Corp., 
Thorold, ON) according to the manufacturer’s instructions. Proteinase K was included in 
the extraction in an effort to increase DNA yields. Extracted DNA was quantified 
fluorometrically using the Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, 
Burlington, ON) and NanoDrop 3300 fluorospectrometer (Fisher Scientific Limited, 
Nepean, ON). Isolated phage genomic DNA was digested using the same restriction 
enzymes HindIII and ClaI (New England Biolabs Inc., Pickering, ON) as employed by 
Davies and Lee (2006).  Extracted DNA was incubated with restriction enzymes for 4 h 
at 37°C. Incubation time was determined experimentally to ensure complete digestion of 
phage DNA and non-specific degradation of DNA bands did not occur. Digested phage 
DNA fragments were separated by agarose gel (0.7% w/v) electrophoresis and visualized 
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with ethidium bromide staining. Gels were soaked in 1 mM MgSO4 solution to remove 
background fluorescence as necessary. RFLP profiles were analyzed with BioNumerics 
software (Applied Maths, Inc., Austin, TX).  
 
Sequencing 
 Eight unique M. haemolytica temperate bacteriophages were selected for genome 
sequence analysis based on several criteria. Phages were chosen to represent different 
virion morphologies, RFLP profiles, and host attributes. Host attributes, including PFGE 
types of M. haemolytica isolates, isolate serotypes and origin of the sample were 
considered (Table 3.1). Phage genomic DNA was prepared from φMH535A, φMH587A, 
φMH622A, φMH1127A, φMH1152A, φMH2256A, φMH3927A, and φMHG8. In order 
to prepare the larger amount of bacteriophage DNA required for whole genome 
sequencing, selected M. haemolytica isolates were induced in quadruplicate. Induction 
procedures were similar to those previously outlined, but additional concentration and 
purification steps by precipitation with polyethylene glycol (PEG) were implemented to 
maximize phage yield and purity (Carlson, 2005). Briefly, 1 μL of RNase A (7,000 
U/mL) was included at the end of phage induction to remove residual bacterial RNA. 
Sodium chloride was added to achieve a final concentration of 0.57 M and samples were 
mixed on ice for 1 h to improve phage precipitation. Phage samples were centrifuged and 
filtered to remove bacterial debris. Phage filtrate was mixed with PEG 8000 (Sigma-
Aldrich Canada Ltd., Oakville, ON) to achieve a concentration of 10% (v/v) and mixed 
on ice for 1 h and samples were stored overnight at 4°C. Phage suspensions were 
centrifuged at 11,000 × g for 20 min at 4°C and the supernatant was carefully removed. 
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Phage pellets were resuspended in 250 μL of SM buffer. Phage DNA was extracted and 
DNA concentration determined as described previously. Subsequent DNA quality control 
assurance and amplification of the eight bacteriophage samples were conducted by 
Eurofins MWG Operon prior to sequencing by GS FLX Titanium series chemistry 
(Roche 454) (Eurofins MWG Operon, Huntsville, AL). Whole genome sequencing 
yielded excellent coverage of all samples ranging from 34.8× to 67.5×. Sequencing data 
was assembled by Celera Assembler (Version 5.3) and critical gaps of selected samples 
were identified and closed by conventional Sanger sequencing technology. 
 
Genome annotation 
 The φMH1152A consensus sequence was used for gene identification and 
annotation. Initial genome annotation was done using myRAST program (Aziz et al., 
2008). SeqBuilder application (DNASTAR, Inc., Madison, WI) was used to visually scan 
the sequence for potential genes. All translated proteins were scanned for homologues 
using BLASTP and PSI-BLAST (Altschul et al., 1990 and 1997). GenBank nr database 
(Benson et al., 2011) and Conserved Domain Database (Marchler-Bauer et al., 2011) 
were used to compare protein coding sequences (CDS). Ribosomal binding sites (RBS) 
were identified using RBSfinder program online and rho-independent terminators were 
identified using MFold (Zuker, 2003) and TransTerm (Ermolaeva et al., 2000). Promoters 
were identified by neural network promoter prediction (Reese, 2001) with visual 
inspection. Transfer RNA (tRNA) genes were screened using Aragorn (Laslett and 
Canback, 2004) and tRNAScan (Lowe and Eddy, 1997). Sequence manipulation and 
graphical representation of phage genome were made using the Geneious v5.4 program 
 63
(Biomatters Ltd., Auckland, New Zealand). The φMH1152A consensus sequence was 
deposited into GenBank database with an accession number JN255163. 
 
Statistical analysis 
 RFLP and PFGE-related analyses were performed using BioNumerics software 
(Applied Maths, Inc., Austin, TX). Dendrograms were generated with UPGMA 
clustering of Dice coefficient values with 1.0% optimization and 1.5% position tolerance 
settings. 
 
3.3 Results 
 Isolated bacteriophages were characterized by TEM for phage morphology, RFLP 
analysis for genetic diversity, and host range analysis for lysis and plaque-forming 
capability. The correlation between host antimicrobial resistance and the presence of 
inducible prophages was also investigated with regard to phages that originated from M. 
haemolytica that exhibited different levels of resistance to enrofloxacin. Eight distinct 
bacteriophages were identified and subsequently sequenced using next generation 454TM 
sequencing technology to gain insights into the genomic makeup of the bacteriophages 
isolated in this study. The sequence information was further evaluated against previously 
published M. haemolytica bacteriophage and bacterial genomes.  
 Preliminary studies on phage induction were performed with reference strain 
BAA410. The published genome of M. haemolytica BAA410 was found to contain a 
complete, inducible prophage (Highlander et al., 2006). The presence of temperate 
bacteriophages in M. haemolytica strain BAA410 was confirmed initially by TEM (Table 
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3.1). This strain was consistently used as a control in subsequent bacteriophage induction. 
Overall, a total of 74 M. haemolytica isolates (two reference plus 72 field strains) were 
induced and screened for temperate bacteriophages. Among these, 56 M. haemolytica 
isolates were confirmed positive for temperate bacteriophages (Table 3.1). This 
accounted for close to 76% of all isolates examined. Each phage was designated as a 
φ[host strain used for phage induction] for identification. For instance, φMHBAA410 
was induced and isolated from BAA410 strain of M. haemolytica (MH). Based on TEM 
images, two major phage morphologies were observed including Myoviridae (Fig. 3.1a 
and Fig. 3.1c) and Siphoviridae (Fig. 3.1b). All phages examined in this study belonged 
to the tailed phages, order Caudovirales. Typical tailed phages contained icosahedral 
heads, but capsids were often shrunken due to sample preparation or the staining 
procedure (Ackermann, 2009), occasionally making morphological identification difficult. 
A total of 29 M. haemolytica isolates produced phages displaying Myoviridae 
morphology. A typical Myoviridae-like phage from φMH755A is presented in Fig. 3.1a, 
showing an icosahedral head and a contractile tail that consists of a central tube with 
sheath located below the capsid. Six Myoviridae-like phages exhibited shorter tails, 
φMH1719A being one of these (Fig. 3.1c). A further 21 M. haemolytica isolates 
produced Siphoviridae-like phages upon induction. A typical Siphoviridae-like phage 
from φMHG8 is shown in Fig. 3.1b, showing a long, non-contractile tail with no sheath. 
Multiple phage morphologies were apparent in single preparations of six of the isolates 
analyzed, with virions resembling both Myoviridae and Siphoviridae phages (Table 3.1).  
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 Fig. 3.1. Representative TEM micrographs of negatively stained virions. φMH755A, 
Myoviridae-like phage (a); φMHG8, Siphoviridae-like phage (b); φMH1719A, 
Myoviridae-like phage (c). Scale bars are 100nm in (a, c), 20nm in (b). 
 
Results from TEM identification of temperate bacteriophages in M. haemolytica 
isolates were used to determine the validity of our enrofloxacin hypothesis. Intermediate 
enrofloxacin susceptible and enrofloxacin susceptible isolates were identified as either 
phage positive or phage negative, but there was no evidence of a statistical correlation (P 
= 0.415). 
 Restriction fragment length polymorphic analysis of phage DNA was performed 
to determine genetic variability of induced bacteriophages from M. haemolytica isolates. 
The resulting patterns were used to characterize and differentiate phages in this study. 
Phage DNA was extracted from 56 M. haemolytica isolates that were identified positive 
for phage by TEM. Profiles were obtained successfully for 40 of these phage isolates 
while DNA yields of the other isolates were too low to generate a viable RFLP pattern. 
Representative RFLP profiles for eight of the phage isolates are depicted in Fig. 3.2. 
Considerable variability was observed for fragment banding patterns between individual 
profiles. Fragment analysis of phage RFLP profiles were performed using BioNumerics 
program. Isolates with multiple phage morphologies were excluded in this analysis to 
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avoid ambiguity. A dendrogram was generated with 14 distinct clusters being identified 
with a relatedness of ≥70% (Fig. 3.3). The cluster analysis showed substantial diversity, 
and phages belonging to each cluster group were designated RFLP types 1-14 (Table 
3.1).  
 
 
Fig. 3.2. Representative RFLP profiles of eight M. haemolytica phage DNA digested with 
HindIII and ClaI (lanes 1-8). Lane 1, φMH535A; lane 2, φMH587A; lane 3, φMH622A; 
lane 4; φMH1127A; lane 5, φMH1152A; lane 6, φMH2256A; lane 7, φMH3927A; lane 
8, φMHG8. PC, positive control, 100ng lambda DNA digested with HindIII and ClaI. 
NC, negative control, contained water instead of DNA template. M, 1kb plus DNA 
ladder. 
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 Fig. 3.3. Dendrogram of RFLP profiles from 35 M. haemolytica phages and a lambda 
DNA (control). Isolate origin (feedlot information), phage morphology, isolate serotype, 
and phage RFLP type data included. A total of 14 phage RFLP types were identified 
based on ≥70% similarity. 
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 Pulsed-field gel electrophoresis (PFGE) is a highly reproducible and 
discriminatory tool for molecular typing of bacteria and has been used to characterize M. 
haemolytica genomes (Klima et al., 2011). Corresponding PFGE profiles of M. 
haemolytica isolates used in this study were selected and analysed using BioNumerics. 
The associations between temperate bacteriophage genomes (RFLP) and host genomes 
(PFGE) were examined in 35 M. haemolytica isolates. Clusters of PFGE profiles were 
generated and compared with M. haemolytica phage RFLP types (Fig. 3.4). Additional 
information such as phage morphology and isolate serotype were included to determine 
correlations among these properties. Isolates with RFLP type 7 were clustered together 
during this analysis and they exhibited >74% relatedness between each other based on 
their corresponding PFGE profiles. Serotypes were closely associated with bacterial 
PFGE profiles (Klima et al., 2011), which were also reflected in phage RFLP type 7. 
Phage morphology did not appear to be correlated with isolate serotype, phage RFLP 
type, or bacterial PFGE profile. 
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 Fig. 3.4. Dendrogram of PFGE profiles from selected M. haemolytica isolates. Phage 
RFLP type, isolate serotype and phage morphology data included. 
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 Host range specificities of eight selected bacteriophages were determined by 
plaque assay against a total of 80 M. haemolytica indicator strains consisting of 10 
reference strains of various serotypes (serotype 1, 2, 5, 6, 7, 8, 9, 12, 14) and 70 field 
strains (serotypes 1, 2, and 6) (Table 3.1). A typical plaque assay with M. haemolytica 
indicator strain 413A is shown in Fig. 3.5. Results from host range analysis are 
summarized in Table 3.2. Zones of lysis ranging from slightly visible to turbid were 
recorded and expressed as number of incidences (frequency) where plaques were 
detected for indicator strains of each serotype. Phage φMH587A generated more plaques 
than other phages, while φMHG8 was the only phage unable to form plaques on any of 
the indicator strains tested. Apart from serotype 2 indicator strains, few plaques were 
formed with either serotype 1 or serotype 8 indicator strains. Most plaques on serotype 1 
indicator strains were formed by φMH1152A. Plaques were absent on serotype 5, 6, 7, 9, 
12, and 14 indicator strains. 
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 Fig. 3.5. Plaque assay of eight phage filtrates spotted on a bacterial lawn of M. 
haemolytica 413A as indicator strain. Negative control contained sterile water instead of 
phage filtrate. A turbid zone of lysis (plaque) is shown with an arrow. 
 
 
Table 3.2. Host range summary of selected eight M. haemolytica temperate 
bacteriophages against M. haemolytica indicator strains of various serotypes. 
 
   Frequency of plaques formed by phage 
   φMH 535A 
φMH 
587A 
φMH 
622A 
φMH 
1127A
φMH 
1152A 
φMH 
2256A 
φMH 
3927A 
φMH 
G8 
  serotype n A B B B C A C D 
1 11 1 0 1 1 9 1 0 0 
2 56 8 50 7 27 11 14 1 0 
5 1 0 0 0 0 0 0 0 0 
6 6 0 0 0 0 0 0 0 0 
7 1 0 0 0 0 0 0 0 0 
8 1 1 1 1 1 1 1 1 0 
9 1 0 0 0 0 0 0 0 0 
12 1 0 0 0 0 0 0 0 0 
Indicator 
strain 
14 1 0 0 0 0 0 0 0 0 
Total number of 
plaques 10 51 9 29 21 16 2 0 
 
A: Phage induced from serotype 1 host. 
B: Phage induced from serotype 2 host. 
C: Phage induced from serotype 6 host. 
D: Phage induced from serotype 8 host. 
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 A summary of sequencing data and assembly result of eight selected phage 
samples is shown in Table 3.3. Preliminary sequence analysis of assembled large contigs 
from each of these phage samples was accomplished by BLAST search using NCBI’s 
nucleotide database. Contigs from φMH535A, φMH587A, φMH1127A, φMH1152A, and 
φMH2256A showed high degree of nucleotide similarity to regions of a published 
complete genome sequence of bacteriophage φMhaA1-BAA410 and bacteriophage 
φMhaA1-PHL101 induced from M. haemolytica serotype A1 (Highlander et al., 2006). 
Partial sequence similarity to bacteriophage φMhaA1-BAA410 also existed in φMHG8 
large contigs, but to a lesser extent. Large contigs from φMH622A exhibited no 
significant alignment with other sequences in the database. Contigs from φMH3927A, 
and φMHG8 also showed limited sequence similarity to small regions of Actinobacillus 
pleuropneumoniae and Actinobacillus succinogenes, while contigs from other samples 
exhibited little similarity to Actinobacillus-related sequences.  
 
Table 3.3. A summary of eight M. haemolytica temperate bacteriophage sequences. 
 Sample 
  
φMH 
535A 
φMH 
587A 
φMH 
622A 
φMH 
1127A 
φMH 
1152A 
φMH 
2256A 
φMH 
3927A 
φMH 
G8 
Total Number of 
Reads 14738 12306 9563 9263 11121 14155 8862 24910 
Total Number of 
Bases 4881131 3992786 3002471 2756307 3502947 4657467 2731940 8283565 
Average Read Length 331 324 313 297 314 329 308 332 
Number of reads 
assembled 12827 10723 8062 7542 9696 12307 7631 22730 
Number of reads too 
short (<64) 324 273 245 291 272 327 196 550 
Number of Contigs 1459 913 516 928 729 1294 549 1998 
Largest Contig 27323 34755 4106 25180 34896 31471 46040 15414 
Total number of 
bases in Contigs 645263 382622 208012 363916 313744 552010 260541 1011590 
Coverage (all reads) 39.49 63.91 67.48 45.72 60.5 55.63 58.54 34.83 
%GC 41.1 41.4 35.7 41.4 41.6 41.2 41.4 41.5 
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 Among eight phage samples, contigs from φMH1152A demonstrated the highest 
sequence similarity and coverage to the genomes of bacteriophage φMhaA1-BAA410 
and φMhaA1-PHL101. To confirm the assembly, PCR reactions were designed and PCR-
generated sequences were integrated. After manual editing, a 34,719 bp consensus 
sequence of φMH1152A genome was constructed. A total of 54 open reading frames 
were predicted from this consensus sequence (Fig. 3.6 and Table 3.4). Predicted 
attachment (att) sites, ribosomal binding sites, promoters, and terminators are also shown 
in Fig. 3.6. Genes encoding tRNA were found to be absent in φMH1152A genome. A 
summary of identified genes with predicted protein function is listed in Table 3.4. The 
φMH1152A consensus sequence was pairwise-aligned to the previously described 
genome of bacteriophage φMhaA1-PHL101. A graphical alignment map is depicted in 
Fig. 3.7, which shows 99.2% sequence similarity between these two genomes. 
Comparisons of φMH1152A consensus sequence to genome sequences of M. 
haemolytica PHL213 (NZ_AASA00000000), M. haemolytica serotype A2 str. OVINE 
(NZ_ACZX00000000), and M. haemolytica serotype A2 str. BOVINE 
(NZ_ACZY00000000) showed various degrees of similarity. Contigs 38, 39, 129, 159 of 
M. haemolytica PHL213 genome contained 99%-100% identical sequences to different 
regions of our φMH1152A consensus sequence and together they roughly covered the 
entire phage sequence with minimal overlaps and gaps. Contigs 00021, 00030, 00073, 
00134 of M. haemolytica serotype A2 str. OVINE genome contained regions that were 
93%-99% identical to regions of φMH1152A sequence, but several gaps were present. 
Regions of contig 00033 of M. haemolytica serotype A2 str. BOVINE genome exhibited 
97% identical sequences and cover 75% of φMH1152A sequence.  
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 Fig 3.6. Genome map of bacteriophage φMH1152A. Predicted genes are numbered from 
1 to 51. Percentage GC content is shown below the gene with a sliding window size of 50 
nucleotides. Predicted attachment (att) sites, ribosomal binding sites (RBS), promotors, 
and terminators are shown with red, green, brown, and orange colored triangles.  
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Table 3.4. Bacteriophage φMH1152A ORF analysis and gene prediction. 
ORF Range (bp)  
Siza 
(aa) Predicted function 
Best BLASTP match 
(organism) 
BLASTP 
e value 
Identities 
(%) 
1 428-1468 346 
capsid portal 
protein Q 
YP_655469.1|capsid portal 
protein Q [Mannheimia 
phage phiMHaA1] 
0 100 
2 1477-3294 605 
phage terminase, 
ATPase subunit 
YP_655470.1|terminase 
ATPase subunit 
[Mannheimia phage 
phiMHaA1] 
0 99 
3 3429-4256 275 
capsid scaffolding 
protein O 
YP_655471.1|capsid 
scaffolding protein O 
[Mannheimia phage 
phiMHaA1] 
0 100 
4 4270-5298 342 
major capsid 
protein N 
YP_655472.1|major  capsid 
protein N [Mannheimia 
phage phiMHaA1] 
0 100 
5 5308-5997 229 
terminase, small 
subunit 
YP_655473.1|terminase 
small subunit [Mannheimia 
phage phiMHaA1] 
2E-167 100 
6 6109-6624 171 
head completion 
protein L 
YP_655474.1|head 
completion protein L 
[Mannheimia phage 
phiMHaA1] 
9E-124 100 
6a 6621-6830 69 
tail synthesis 
protein X 
YP_655475.1|tail synthesis 
protein X [Mannheimia 
phage phiMHaA1] 
1E-45 100 
7 6839-7045 68 possible holin 
YP_655476.1|possible holin 
[Mannheimia phage 
phiMHaA1] 
1E-42 100 
8 7038-7604 188 endolysin 
YP_655477.1|endolysin 
[Mannheimia phage 
phiMHaA1] 
3E-138 100 
9 7601-8056 151 
conserved 
hypothetical phage 
protein 
YP_655478.1|hypothetical 
bacteriophage protein 
[Mannheimia phage 
phiMHaA1] 
2E-106 100 
10 8405-8626 73 
hypothetical Zinc-
finger containing 
protein 
YP_655479.1|hypothetical 
protein MhaA1p11 
[Mannheimia phage 
phiMHaA1] 
3E-47 100 
11 8623-9108 161 
tail completion 
protein R 
YP_655480.1|tail 
completion protein R 
[Mannheimia phage 
phiMHaA1] 
4E-115 100 
12 9101-9559 152 
tail synthesis 
protein S 
YP_655481.1|tail synthesis 
protein S [Mannheimia 
phage phiMHaA1] 
2E-107 100 
13 9927-12839 970 tail protein T 
YP_655483.1|tail protein T 
[Mannheimia phage 
phiMHaA1] 
0 100 
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14 12904-13080 58 
conserved 
hypothetical protein
YP_655484.1|hypotheticalp
rotein MhaA1p16 
[Mannheimia phage 
phiMHaA1] 
1E-34 100 
15 13073-13360 95 
conserved 
hypothetical protein
YP_655485.1|hypotheticalp
rotein MhaA1p17 
[Mannheimia phage 
phiMHaA1] 
1E-62 100 
16 13489-14094 201 
baseplate assembly 
protein V 
YP_655486.1|baseplate 
assembly protein V 
[Mannheimia phage 
phiMHaA1] 
6E-145 100 
17 14094-14429 111 
baseplate assembly 
protein W 
YP_655487.1|baseplate 
assembly protein W 
[Mannheimia phage 
phiMHaA1] 
2E-78 100 
18 14426-15343 305 
baseplate assembly 
protein J 
YP_655488.1|baseplate 
assembly protein J 
[Mannheimia phage 
phiMHaA1] 
0 100 
19 15330-15962 210 
tail formation 
protein I 
YP_655489.1|tail formation 
protein I [Mannheimia 
phage phiMHaA1] 
1E-153 100 
20 15965-18244 759 
variable tail fiber 
protein H 
YP_655490.1|variable tail 
fiber protein H [Mannheimia 
phage phiMHaA1] 
0 99 
21 18245-18487 80 
conserved 
hypothetical protein
YP_655491.1|hypothetical 
protein MhaA1p23 
[Mannheimia phage 
phiMHaA1] 
3E-54 99 
22 18477-18596 39 
conserved 
hypothetical protein
ABD90652.1|hypothetical 
protein [Mannheimia phage 
phiMhaA1-BAA410] 
1E-13 100 
23 18652-18798 48 
conserved 
hypothetical protein
ABD90625.1|hypothetical 
protein [Mannheimia phage 
phiMhaA1-BAA410] 
1E-28 100 
24 18905-20086 393 
phage tail sheath 
protein  
YP_655492.1|tail sheath 
protein FI [Mannheimia 
phage phiMHaA1] 
0 100 
25 20095-20601 168 
major tail tube 
protein 
YP_655493.1|tail tube 
protein FII [Mannheimia 
phage phiMHaA1] 
3E-120 100 
26 20680-20994 104 phage tail protein E 
YP_655494.1|tail protein E 
[Mannheimia phage 
phiMHaA1] 
1E-68 100 
26a 20970-21134 54 
possible of 
extension protein E' 
of E 
ZP_05850311.1|P2 GpE 
family phage tail protein 
[Haemophilus influenzae 
NT127] 
4E-12 60 
27 21198-21545 115 
conserved 
hypothetical protein
YP_655495.1|hypotheticalp
rotein MhaA1p28 
[Mannheimia 
phagephiMHaA1] 
1E-75 100 
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28 21547-21984 145 phage tail protein U
YP_655496.1|tail proteinU 
[Mannheimia phage 
phiMHaA1] 
4E-103 100 
29 21984-23180 398 phage tail protein D
YP_655497.1|tail proteinD 
[Mannheimia phage 
phiMHaA1] 
0 97 
30 23363-24169 268 
conserved 
hypothetical phage 
protein 
ZP_04976993.1|hypothetic
al bacteriophage protein 
[Mannheimia haemolytica 
PHL213] 
0 100 
31 24204-24464 86 
conserved 
hypothetical protein
YP_655499.1|hypothetical 
protein MhaA1p32 
[Mannheimia phage 
phiMHaA1] 
4E-56 100 
32 24564-24893 109 
conserved 
hypothetical protein
YP_655500.1|hypothetical 
protein MhaA1p33 
[Mannheimia phage 
phiMHaA1] 
9E-74 100 
32a 24894-24974 26 
conserved 
hypothetical protein
ZP_05991374.1|hypothetic
al protein COI_0691 
[Mannheimia haemolytica 
serotype A2 str. OVINE] 
4E-9 96 
33 24992-25510 172 
conserved 
hypothetical protein
YP_655501.1|hypothetical 
protein MhaA1p34 
[Mannheimia phage 
phiMHaA1] 
2E-123 100 
34 25514-26200 228 CI repressor 
YP_655502.1|CI repressor 
[Mannheimia phage 
phiMHaA1] 
3E-169 100 
35 26324-26536 70 
Cro family 
repressor 
YP_655503.1|Cro repressor 
[Mannheimia phage 
phiMHaA1] 
9E-43 100 
36 26520-26801 93 
conserved 
hypothetical protein
YP_655504.1|hypotheticalp
rotein MhaA1p37 
[Mannheimia phage 
phiMHaA1] 
2E-62 100 
37 27013-27285 90 
conserved 
hypothetical protein
YP_655505.1|hypotheticalp
rotein MhaA1p38 
[Mannheimia phage 
phiMHaA1] 
2E-61 100 
38 27368-27700 110 
conserved 
hypothetical protein
YP_655506.1|hypotheticalp
rotein MhaA1p39 
[Mannheimia phage 
phiMHaA1] 
3E-71 100 
39 27713-28006 97 
conserved 
hypothetical protein
YP_655507.1|hypotheticalp
rotein MhaA1p40 
[Mannheimia phage 
phiMHaA1] 
3E-68 100 
40 28018-28146 42 
conserved 
hypothetical protein
ZP_04976983.1|hypothetic
al protein MHA_0402 
[Mannheimia haemolytica 
PHL21] 
1E-23 100 
41 28158-28400 80 
conserved 
hypothetical protein
YP_655508.1|hypotheticalp
rotein MhaA1p41 
[Mannheimia phage 
4E-53 100 
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phiMHaA1] 
42 28397-28729 110 
conserved 
hypothetical protein
YP_655509.1|hypotheticalp
rotein MhaA1p42 
[Mannheimia phage 
phiMHaA1] 
2E-78 100 
43 28726-31086 786 replication protein A
YP_655510.1|replication 
protein A [Mannheimia 
phage phiMHaA1] 
0 100 
44 31099-31431 110 
conserved 
hypothetical protein
YP_655511.1|hypotheticalp
rotein MhaA1p44 
[Mannheimia phage 
phiMHaA1] 
6E-74 100 
45 31431-31883 150 
single-stranded 
DNA-binding 
protein 
YP_655512.1|single-
stranded DNA binding 
protein [Mannheimia phage 
phiMHaA1] 
7E-108 100 
46 31894-32226 110 
conserved 
hypothetical phage 
protein 
ZP_04976977.1|hypothetic
al bacteriophage protein 
[Mannheimia haemolytica 
PHL213] 
2E-78 100 
47 32216-32485 89 
conserved 
hypothetical protein
YP_655514.1|hypotheticalp
rotein MhaA1p47 
[Mannheimia phage 
phiMHaA1] 
4E-59 100 
48 32460-32750 96 
conserved 
hypothetical protein
YP_655515.1|hypotheticalp
rotein MhaA1p48 
[Mannheimia phage 
phiMHaA1] 
7E-66 100 
49 32885-33001 38 
conserved 
hypothetical protein none   
50 33020-33202 60 
conserved 
hypothetical protein
YP_655516.1|hypothetical 
protein MhaA1p49 
[Mannheimia phage 
phiMHaA1] 
1E-33 100 
51 33480-34478 332 integrase 
YP_655517.1|integrase 
[Mannheimia phage 
phiMHaA1] 
0 100 
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 Fig. 3.7. Alignment map showing regions of nucleotide similarity between published 
sequence of bacteriophage φMhaA1-PHL101 and consensus sequence of φMH1152A. 
Sequence disagreements are shown in black. 
 
3.4 Discussion 
 Unknown phages have traditionally been identified by electron microscopy, 
which has become a crucial feature for comparative virology and phage classification 
(Ackermann, 2009). The bacteriophage morphologies observed here were relatively 
diverse within the tailed phage group, which is consistent with previous studies that 
identified three major tail morphologies from M. haemolytica temperate bacteriophages 
belonging to Myoviridae, Siphoviridae, and Podoviridae (Davies and Lee, 2006). Similar 
morphologies were also observed in bacteriophages of a related organism, Pasteurella 
multocida (Ackermann and Karaivanov, 1984). Lysogeny is a common feature in many 
bacterial populations (Weinbauer, 2004), including M. haemolytica. Previous studies 
have shown that bacteriophage particles were widely distributed in M. haemolytica with 
75% of 32 M. haemolytica isolates examined containing inducible phages (Davies and 
Lee, 2006). The prevalence of phages was similar in this study, where 76% of 74 M. 
haemolytica isolates examined contained inducible bacteriophages.  
 Uniquely, in this study multiple phage types were recovered from single M. 
haemolytica isolates. This was observed on several occasions where two different phage 
morphologies (Myoviridae and Siphoviridae) were present in single isolate preparations. 
Although it is common to find multiple prophages in the genomes of E. coli O157:H7, 
Streptococcus pyogenes, Bacillus subtilis, and many other bacterial species (Canchaya et 
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al., 2003b; Casjens, 2003), and the induction of multiple prophages has been 
demonstrated in a marine bacterium Silicibacter sp. strain TM1040 (Chen et al., 2006), 
previous studies have not reported multiple prophage induction from M. haemolytica. 
The M. haemolytica strain BAA410 contained at least two intact prophages in its genome 
(Gioia et al., 2006) with a P2-like phage, two Mu-like phages, and λ-like fragments being 
detected in the genome. Typically P2-like and Mu-like phages are myoviruses, while λ is 
a siphovirus (Guttman et al., 2005). The combination of myovirus and siphovirus 
sequences in M. haemolytica genome might explain our observation of multiple phage 
morphologies from strain BAA410 and other phage preparations (Table 3.1), assuming 
that these prophage sequences were complete and inducible. Prophages can exhibit 
different levels of inducibility and some prophage-like elements in the genome can be 
defective or non-mitomycin C-inducible (Casjens, 2003), such as certain prophages 
identified in Silicibacter sp. strain TM1040 (Chen et al., 2006). 
 Phage RFLP analysis provided a rapid assessment of genetic diversity of the 
induced bacteriophages (Carlson, 2005; Pullinger et al., 2004). Successful restriction 
enzyme digestion also confirmed that phage genome composition was indeed double-
stranded DNA. Results were used to characterize and differentiate phages in this study. 
Among 35 phage RFLP profiles obtained, substantial genetic variation was evident from 
the patterns generated with double enzyme digestions. At ≥70% RFLP relatedness, three 
groups of phages (587A and 1040A; 3721A, 4387A, and 1498A; 1492A and 1745A) 
showed identical phage RFLP profiles often exhibiting the same phage morphology and 
same host attributes including isolate serotype, sampling location, or sampling time 
(arrival or exit) (Fig. 3.3). This was expected as prophages can constitute a sizable part of 
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the host genome and account for biological differences between isolates of the same 
species (Canchaya et al., 2003b; Casjens, 2003), including changes in host restriction 
system, sensitivity to antimicrobials, and host immunity from phage re-infection (Casjens, 
2003; Clokie and Kropinski, 2009; Willey et al., 2008). Interestingly, field isolates that 
contained multiple phages were all collected from the same feedlot. This suggests 
multiple phage induction usually occurs in a particular group of M. haemolytica isolates 
and that these phages are geographically dispersed. Cluster analysis of host PFGE 
profiles showed a slight correlation with phage RFLP type 7 cluster (Fig. 3.4). Results 
from phage RFLP analysis suggest prophages or prophage-like sequences are important 
contributors to bacterial diversity and bacterial evolution (Brüssow et al., 2004; Casjens, 
2003; Hendrix et al., 1999), and the exchange of genetic information between bacteria 
may be carried out by prophages through horizontal transfer (Banks et al., 2002; Briani et 
al., 2001; Ohnishi et al., 2001).  
 Host range analysis was used to test the efficiency of a phage’s ability to infect 
and develop in a particular host. Plaque formation indicates phages are capable of 
infecting and lysing the bacterial strains examined. This approach may be used as a 
discriminatory tool that compliments RFLP analysis, as host range analysis of the eight 
selected bacteriophages showed distinct lysis patterns on a collection of indicators strains 
(Table 3.2). Overall, phages exhibited a limited host range that was serotype specific, an 
observation similar to previous findings (Davies and Lee, 2006). Plaques were observed 
on serotype 1, serotype 2, and serotype 8 indicator strains. No plaques were formed on 
any other serotypes examined. Typically, temperate phages provide the host immunity 
from re-infection by the same phage or other phages of the same immunity group 
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(Casjens, 2003; Clokie and Kropinski, 2009; Gill and Hyman, 2010; Guttman et al., 2005; 
Willey et al., 2008). Since the majority of our indicator strains are known to harbour 
prophages, their presence might have prevented infections of related phages. None of the 
phages induced were able to form clear plaques such as one would see from a strictly 
lytic bacteriophage. This was probably due to lysogenization of some bacteria within the 
plaque, analogous to typical turbid plaques made by phage λ or by temperate phages in 
general (Gill and Hyman, 2010; Guttman et al., 2005).  
 A variety of antimicrobials are used for treating animals infected with BRD 
(Fulton, 2009). Previous studies demonstrated that the presence of prophage increased the 
sensitivity of M. haemolytica to a broad-spectrum fluoroquinolone, danofloxacin, and 
exposure to this antimicrobial induced prophage in M. haemolytica (Froshauer et al., 
1996). Here we set out to determine if a similar effect occurred for enrofloxacin, another 
fluoroquinolone antimicrobial compound. Since no enrofloxacin-resistant isolates were 
detected in our collection of M. haemolytica field isolates (Klima et al., 2011), 33 M. 
haemolytica field isolates with high enrofloxacin susceptibility and 33 field isolates with 
low enrofloxacin susceptibility were selected and the presence of phage in each isolate 
was determined. Our results showed there was no significant correlation (P = 0.415) 
between presence of inducible phage and enrofloxacin susceptibility in M. haemolytica. 
Both danofloxacin and enrofloxacin inhibit bacterial DNA gyrase (Elkholy et al., 2009; 
Froshauer et al., 1996), which result in DNA damage during replication. When bacteria 
activate their SOS system in response to DNA damage, RecA protein is activated, which 
in turn degrades one of the repressors in the phage lytic pathway and promotes phage 
induction (Clokie and Kropinski, 2009; Froshauer et al., 1996). Even though the mode of 
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action is similar for these two antimicrobial compounds, we did not find increased 
enrofloxacin sensitivity from lysogenic M. haemolytica isolates. Further work will be 
necessary to investigate the relationship of antimicrobial sensitivity and phage induction. 
 Prophages are prevalent in many widely diverse bacterial species. They can 
contribute important biological properties to bacterial hosts. For instance, lysogenic 
conversion of the host can offer protection against further phage infection and increase 
the virulence of a pathogenic host (Casjens, 2003). To study the evolution of both 
bacteriophages and their hosts, nucleotide sequence analysis is essential. Complete 
sequences of fully functional double stranded DNA tailed phage genomes have already 
been determined from various bacteria (Casjens, 2003). This includes some well-studied 
E. coli phages, such as temperate phage λ and T-series of obligately lytic phages 
(Guttman et al., 2005). It is often difficult to detect homologies in newly sequenced 
phage genomes due to the extreme diversity among bacteriophage (Hendrix et al., 1999). 
Therefore, a newly discovered phage is expected to have novel genes as compared to 
closely related phages (Casjens, 2003), and approximately half of the sequenced phage 
genes can be found to be novel during genomic analyses (Hambly and Suttle, 2005). This 
is not completely in agreement with the phage sequences we obtained, though none of 
them were identical, some were extremely similar. The sequence similarity can be 
contributed by extensive genome mosaicism, which is common in closely related phages. 
This genome mosaicism is characterized by patches of high sequence similarity separated 
by non-homologous regions (Casjens, 2003; Skurnik et al., 2007), which was evident 
among the five phage sequences we obtained that closely aligned with bacteriophage 
φMhaA1-PHL101. Patches of similar phage sequences seem to be prominent and 
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widespread in our collection of M. haemolytica, even though they were induced from 
different M. haemolytica strains with different serotypes and sampling locations. 
φMH1152A consensus sequence exhibited extremely high sequence identity to φMhaA1-
PHL101. It also aligned well with contigs of all three complete M. haemolytica genomes 
currently available in the database. This is expected as homologs between coding regions 
in M. haemolytica PHL213 and M. haemolytica serotype A2 ovine and bovine strains 
share 95% to 99% nucleotide identity (Lawrence et al., 2010a). Although φMH1152A 
showed patches of very high sequence identity to these M. haemolytica genomes, 
alignments were not always found on the same contig. This was probably due to large-
scale inversions and rearrangements that were identified among these M. haemolytica 
genomes (Lawrence et al., 2010a). Overall, the prevalence and sequence similarity from 
φMH1152A consensus sequence suggests widespread horizontal transfer of genetic 
material among phages and bacteria (Brüssow and Hendrix, 2002; Casjens, 2003, 
Hendrix et al., 1999; Skurnik et al., 2007), and similar phages are widely distributed 
geographically (Hatfull et al., 2006).  
 In conclusion, the diversity of temperate bacteriophages has been successfully 
measured and examined from a specific group of M. haemolytica strains that are broadly 
representative of our entire M. haemolytica collection. These phages were characterized 
extensively in terms of morphology, host specificity, genomic diversity, and comparative 
genomics. Lysogeny is known to be widespread in bacteria and a broad range of 
temperate bacteriophages was found in a significant portion of M. haemolytica strains 
used in this study. Whole genome sequencing was carried out with eight selected phages 
and one consensus sequence was constructed which showed high degree of sequence 
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homology to a previously characterized φMhaA1-PHL101 genome and regions of three 
M. haemolytica bacterial genomes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 86
CHAPTER FOUR 
4.1 Conclusions 
 The attempt to isolate a strictly lytic bacteriophage specific to M. haemolytica in 
this study was unsuccessful in spite of an intensive and comprehensive screening with 
various methodological approaches. Several explanations have been suggested earlier as 
to why this task was difficult to accomplish. Among these, CRISPR-mediated phage 
resistance seems to be the most probable cause since it has been proven experimentally in 
other bacterial species and CRISPR sequences have been identified in the M. haemolytica 
genome (Lawrence et al., 2010b). The techniques and knowledge acquired during the 
lytic bacteriophage work were proven valuable for subsequent temperate bacteriophage 
characterization. Optimal bacterial growth and plating conditions were crucial in 
temperate bacteriophage induction and analysis, which were determined by 
experimenting with different phage isolation and detection methods. Utilization of these 
techniques in temperate bacteriophage work also confirmed that these procedures were 
indeed capable of identifying potential lytic bacteriophages from the environment. In 
addition, these results will provide insight in future experimental design and sampling 
methods when similar lytic bacteriophage studies are to be conducted. In this study, 
collected samples constituted a limited geographic distribution, the exact nutrient 
requirement of the lytic bacteriophage was unclear, and variables such as transport 
medium, transport time, and processing of raw sample may negatively impact 
bacteriophage integrity and infectivity. Factors such as these can all have significant 
influences on successful phage isolation, which should be carefully considered. 
 Temperate bacteriophages were successfully induced and isolated from a group of 
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M. haemolytica strains. These temperate phages were extensively characterized, including 
sequencing of eight selected phages. Although this study only summarizes preliminary 
sequencing results, further in-depth bioinformatic and genomic analysis will reveal the 
significance and variations between these temperate bacteriophage genomes, and the 
molecular biology of temperate bacteriophages in general. These phage genome 
sequences will provide better understanding of contribution of phage to bacterial 
pathogenesis and their potential for treating bacterial infections (McGrath et al., 2004). 
These objectives can be accomplished by identifying sequences of prophage-encoded 
virulence factors in pathogenic bacteria, and sequences of specific phage-encoded 
enzymes that can be incorporated in a targeted phage-derived therapeutic (McGrath et al., 
2004). The evolutionary history and lifestyle of these phages can be elucidated by 
performing a detailed comparative genomic analysis (Gill and Hyman, 2010; McGrath et 
al., 2004), which will also assist in a more consistent taxonomic classification of phages. 
Additionally, the sequencing information may improve future prophage recognition, 
annotation, and studies of different types of non-homologous (convergent) gene modules 
that are used for a particular function by some temperate phages (Casjens, 2003). 
Accumulation of novel phage sequence information will assist in recognition of 
conserved phage morphogenetic proteins such as portal proteins or terminases. This will 
facilitate detection of similar phages from the environment and global analysis of 
prophage sequences using molecular tools such as DNA array analysis or PCR 
amplification (Casjens, 2003).  
 Typically, temperate phages are unfavorable candidates for therapeutic 
applications due to their abilities to carry out lysogenic conversion and potential 
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exchange of virulence genes with the target bacterium by generalized transduction (Gill 
and Hyman, 2010; Johnson et al., 2008; Kutateladze and Adamia, 2010; Skurnik et al., 
2007). Nevertheless, temperate phages are often more easily isolated so various 
alternative strategies have been derived. One approach is to genetically modify temperate 
phages to become permanently lytic (Goodridge, 2010). An example of this method was 
accomplished by generating vir gene mutants of temperate bacteriophages that were 
repressed for lysogeny and capable of infecting Propionibacterium acnes lysogens 
(Rapson et al., 2003). Alternatively, temperate phages can be engineered to express 
bacteria-toxic genes or reduce bacterial pathogenicity during lysogeny (Gill and Hyman, 
2010; Schaak, 2003). It should be noted that these virulent derivatives of temperate phage 
are still considered members of their phage families (Carlson, 2005). The effectiveness of 
using temperate phages as a therapeutic was determined in two studies where lysogenic 
phages were isolated from induced cultures of S. aureus and successfully used in 
treatment of S. aureus infections in mice (Capparelli et al., 2007; Matsuzaki et al., 2003). 
In addition, the use of cocktails containing phages of different host ranges may avoid the 
problems caused by lysogeny, where a lysogen formed by one phage will remain 
susceptible to a second phage within the cocktail (Gill and Hyman, 2010). As phage 
genome sequences became available, one can confirm the absence of known toxin and 
drug-resistance genes or determine the genes encoding lytic enzymes. Genes of interest 
can then be cloned to create recombinant proteins exhibiting lytic activities, which may 
be an effective solution to control bacterial infections (Fischetti, 2005; Loessner et al., 
1998). Alternatively, identification of potential phage-encoded phage resistance genes in 
prophage genome sequences of different bacterial species can be used to develop 
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recombinant phage resistance system against harmful bacteriophages that infect 
economically important bacteria such as members of the lactic acid bacteria used in 
fermentation processes (McGrath et al., 2004). 
 BRD is the leading cause of morbidity and mortality in commercial feedlot cattle 
and results in substantial financial losses from reduced feed efficiency and carcass quality 
(Duff and Galyean, 2007). M. haemolytica has been implicated as the predominant 
bacterial pathogen associated with BRD (Duff and Galyean, 2007; Gioia et al., 2006; 
Griffin et al., 2010). More efficacious methods to control and prevent infection by M. 
haemolytica would have a positive impact on beef feedlot industry in Canada. One 
possibility lies on the prospect of phage therapy. This study investigated the presence of 
strictly lytic bacteriophage(s) specific to M. haemolytica from nasopharyngeal and water 
samples, and the diversity of temperate bacteriophages induced from M. haemolytica. 
Even though it is less favourable to utilize temperate phages in phage therapy and as an 
alternative mitigation strategy for BRD infection, the knowledge acquired from temperate 
phage research is imperative in understanding interactions between bacteriophage and its 
host. A wealth of information can be retrieved from the sequenced temperate phage 
genomes, which will serve as a foundation for future studies such as utilizing lytic 
components of temperate phage to control bacterial infection.  
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